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ARR   Annual relapse rate 
BMI   Body mass index, kg/m2 
CI   Confidence interval 
CIS   Clinically isolated syndrome 
CNS    Central nervous system 
DMT   Disease modifying therapy 
EAE   Experimental autoimmune encephalomyelitis 
EBV   Epstein Barr Virus 
EDSS   Expanded Disability Status Scale 
EnvIMS  Environmental Risk Factors in Multiple Sclerosis  
EnvIMS-Q            The questionnaire in the EnvIMS study 
FRS    Figure rating scale  
GWAS  Genome wide association study 
HLA   Human leucocyte antigen  
IFN-β   Interferon beta 
IL   Interleukin  
IM   Infectious mononucleosis 
ITT   Intention to treat 
IV   Instrumental variable 
MHC   Major histocompatibility complex 
MR   Mendelian randomization 
MRI   Magnetic resonance imaging 
MS   Multiple sclerosis 
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NEDA  No evidence of disease activity 
NHS   Nurses Health Study 
NO   Nitric oxide 
OFAMS  Omega-3 Fatty Acids in Multiple Sclerosis 
OR   Odds ratio 
PA   Physical activity 
PASAT  Paced Auditory Serial Addition Test 
PPMS   Primary progressive multiple sclerosis 
RCT   Randomized placebo-controlled trials 
RIS   Radiologically isolated syndrome 
RR    Relative risk or rate ratio 
RRMS  Relapsing-remitting multiple sclerosis  
SD   Standard deviation 
SNP   Single nucleotide polymorphism 
SPMS   Secondary progressive multiple sclerosis 
SZA   Solar zenith angle 
Th   T helper lymphocyte   
TNF   Tumor necrosis factor  
Treg   T regulatory cell 
UVB   Ultraviolet B  
WHO   World Health Organization 
1,25(OH)2D  1,25-dihydroxyvitamin D   





Background: Multiple sclerosis (MS) is a disabling inflammatory disease of the 
central nervous system (CNS) likely caused by genetic susceptible variants and 
environmental triggers. Low vitamin D levels and smoking are already established risk 
factors for MS, while obesity and physical activity may also influence the risk. In 
addition, some of these factors are associated with disease course in MS, but less is 
known about their potential long-term effects on MS.  
Objectives: In this thesis, we examined (i) the association between body size and MS 
risk across different geographical areas (Paper 1), (ii) whether frequency and intensity 
of physical activity in adolescence may be an independent risk factor for MS (Paper 2) 
and (iii) whether vitamin D levels, tobacco use and body mass index (BMI) can 
influence long-term disability progression in MS (Paper 3).   
Methods and materials: In Paper 1 and 2, we used retrospective self-reported data 
from a large multinational population-based case-control study on environmental and 
lifestyle factors in MS (the EnvIMS study). The study on body size and MS risk in 
Paper 1 was based on self-reported body sizes on a 9-figure scale, at 5-year intervals, 
from age 5 to age 30 years in Norway and Italy. The study on physical activity (PA) 
and MS risk in Paper 2 was based on reported average weekly amounts of light and 
vigorous PA during adolescence in Norway, Sweden and Italy. We used logistic 
regression models to examine the associations between lifestyle factors and the risk of 
MS, with adjustment for relevant covariates. 
For Paper 3, we had available baseline and 10-year follow-up data from 80 patients 
who initially participated in a randomized study on omega-3 fatty acids treatment in 
MS (the OFAMS study). In linear regression models, we examined the association 
between mean baseline levels of serum 25-hydroxyvitamin D (25(OH)D), serum 
cotinine (a nicotine metabolite) and BMI, and 10-year disability progression given by 
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the 10-year change in Expanded Disability Status Scale (EDSS) score. We also 
examined the importance of seasonal fluctuations of 25(OH)D on this association.  
Results: In Paper 1, a large body size (body figure 6-9) was significantly associated 
with increased MS risk in Norway from age 15- 25 years. The association was strongest 
at age 25, with an age-adjusted odds ratio (OR) of 2.10 (95% confidence interval (CI): 
1.08-4.09) for men and 1.48 (95% CI: 0.94-2.32) for women, compared to a “normal 
weight” body size 3. Further adjusting for smoking and outdoor activity gave similar 
estimates. In Italy we found no clear association between body size and the risk of MS, 
but after disease onset, the controls in both countries reported larger body sizes relative 
to the cases.  
In Paper II, the pooled analyses for Norway, Sweden and Italy showed that vigorous 
PA ≥ 3 hours compared to < 1 hour per week was associated with a reduced risk of MS 
with an age- and sex-adjusted OR of 0.74 (95% CI: 0.63-0.87). We found similar 
estimates in country-specific analyses, also after adjusting for other established risk 
factors. No clear evidence of reverse causation explaining this association was 
observed in a subgroup analysis, excluding participants with disease onset within 10 
years from reported PA.  
In Paper 3, one standard deviation (SD; 18.7 nmol/L) increase in seasonally adjusted 
25(OH)D levels during the OFAMS baseline study was associated with 0.45 point 
(95% CI: -0.75 to -0.16) less change in EDSS score after 10 years, in a model adjusting 
for sex, age and baseline EDSS score. There was a significant dose-response 
relationship across quartiles of 25(OH)D levels (p for trend = 0.024). The association 
was mainly driven by low 25(OH)D levels during spring and seasonally adjusted levels 
below 80 nmol/L. For BMI and tobacco use, no significant associations were observed, 




Conclusions: A large body size during childhood and young adulthood was associated 
with increased risk of MS among men and women in Norway, but less so in Italy. 
Higher amounts of regularly vigorous PA were associated with lower MS risk across 
different geographical areas, also after adjustment for potential confounders. Higher 
levels of 25(OH)D during a two-year period were associated with less 10-year 
disability progression, which appeared to be driven by low spring levels. Our findings 
suggest that healthy lifestyle changes during young ages may influence the risk of 
developing MS in a beneficial way, and that better long-term outcomes can be achieved 
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1.1 Multiple Sclerosis- prevalence and distribution 
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the 
central nervous system (CNS). It typically affects young adults with a peak incidence 
from 25 to 35 years of age,1 and a female to male ratio of around 2-3:1.2 Worldwide, 
there are around 2.2 million prevalent cases of MS, with the highest age-standardised 
prevalence (>120 per 100 000) in North-America and some northern European 
countries, moderate (60-120 per 100 000) in other European countries and Australasia, 
and lowest (<60 per 100 000) in countries closer to the equator, and Asia (Figure 1).3 
The distribution shows a clear latitude gradient in some, but not all parts of the world,4 
while an inverse or absent gradient has been observed at higher latitudes,5,6 including 
Norway.7 These geographical and latitudinal variations likely reflect both genetic and 
environmental contributions to the disease.5  
 
Figure 1. Age-standardised multiple sclerosis prevalence per 100 000 population in 
2016; men and women combined. Reprinted by permission from the Creative 
Commons CC-BY license: Adapted from GBD 2016 Multiple Sclerosis Collaborators, 
Lancet Neurology 2019; 18: 281.3   
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Over the years, both prevalence and incidence rates have been rising in many parts of 
the world,3,8-10 predominantly observed in women compared to men.9,10 The increased 
prevalence rates may be explained by earlier diagnosis through changes and revisions 
of diagnostic criteria,11,12 longer survival,13 and better case ascertainment through 
improved diagnostic tools, such as magnetic resonance imaging (MRI) (affect both 
prevalence and incidence).14 The increased incidence in women relative to men is more 
challenging to explain by sex-independent or genetic factors, and is more likely to 
reflect changes in environmental exposures or nutrition.2  
1.2 Pathology and immunological mechanisms in MS 
The pathology of MS involves demyelinated white and grey matter lesions,15 axonal 
injury, and progressive neuronal loss.16 While demyelination is a likely consequence 
of inflammation, neurodegeneration seems to be driven by oxidative stress and 
mitochondrial injury.17 Although most observations suggest that inflammation likely 
precedes neurodegeneration,18 the immunopathogenic mechanisms that trigger and 
maintain MS are complex and not fully understood.19 Inflammation and 
neurodegeneration probably coexist at all stages of the disease,20 and some 
neurodegenerative processes may even appear independent of inflammation.18,19 
Further, there is an ongoing debate whether MS is initiated by an extrinsic event outside 
the CNS (the outside-in theory), or an intrinsic event within the CNS (the inside-out 
theory).18 In either way, both genetic21 and experimental evidence points towards a 
contribution of both adaptive (autoreactive T and B cells and defective T regulatory 
(Treg) cells) and innate immune cells (microglia, macrophages and astrocytes) in the 
pathogenesis of MS.19,22 The T cells are dominated by a shift towards pro-inflammatory 
CD4+ T helper (Th) 17 and Th1 cell pools.22 The beneficial effect of anti-CD 20 
therapies23,24 for MS suggests that antigen-presenting B cells and their interaction with 
pathogenic T cells may be the main inducer of the immune cascade in MS.25 
Epidemiological and experimental evidence also suggests that environmental risk 
factors may be crucial for disease onset through various immunological pathways.19 
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1.3 Disease course and diagnosis  
Traditionally, MS has been divided into two distinct clinical phenotypes26 from onset: 
The majority of patients (85-90%) develop a relapsing-remitting MS (RRMS) 
characterized by symptomatic relapses of neurologic dysfunction with full or partial 
recovery between the relapses. The remaining 10-15% have a primary progressive MS 
(PPMS) with gradual disease progression and no distinct relapses.27,28 Typical MS 
symptoms include visual disturbances, weakness, dyscoordination, sensory loss, and 
changes in bowel and bladder control, as well as more vague symptoms such as 
cognitive impairment and fatigue.29 Subclinical activity can be seen as white matter 
lesions on MRI scans of the brain and spinal cord with typical distribution, 
morphology, evolution and signal abnormalities.14 The disease progression can be 
monitored by the validated and widely used Expanded Disability Status Scale (EDSS) 
ranging from 0, which refers to no symptoms, to 10, which refers to death due to MS.30 
The lower EDSS scores from 0 to 3.5 are mainly determined by ratings in the 
Functional System Scores which includes seven “functional systems” of neurological 
deficits, 30 while the EDSS scores from 4 to 7 are mainly based on walking impairment. 
The highest scores from 7 to 9.5 represent severe disability that affects activity of daily 
living (Figure 2). Before the treatment era, the distribution of EDSS scores in MS 
populations had a typical bimodal shape.31,32 
Many RRMS patients eventually develop secondary progressive MS (SPMS) 
dominated by progression with or without occasional relapses and plateaus.26 A 
diagnosis of MS requires “dissemination in time and space”, which in earlier days was 





Figure 2. The Expanded Disability Status Scale (EDSS) and the factors that determine 
overall score; a typical bimodal distribution over the EDSS have been observed in 
natural history MS populations. Reprinted by permission from the Creative Commons 
Licence: CNS Drugs.2017; 31(3):2017-236.34 
 
In 2001, these criteria were replaced by the McDonald criteria35 with the latest revisions 
made in 2017,12 where clinical and paraclinical evidence (MRI lesions and oligoclonal 
bands in the cerebrospinal fluid) of disease activity are of equal importance to confirm 
the dissemination in time and space needed for a definitive diagnosis of MS.12 In 
addition, the paraclinical evidence of demyelinating activity not explained by other 
conditions has introduced two pre-clinical MS entities that may progress to definitive 
MS with time; clinical isolated syndrome (CIS) and radiologically isolated syndrome 
(RIS).36 After onset, the disease course is unpredictable and varies highly between 
individuals. Important demographic, clinical and radiological prognostic factors for 
earlier irreversible disability are older age, male gender, progressive disease from 
onset, number of relapses during the first five years, pyramidal onset symptoms, spinal 
cord lesions and MRI lesion load.37-41  
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1.4 Disease-modifying therapies and prognosis  
Before the treatment era of disease-modifying therapies (DMT) for MS, most RRMS 
patients developed SPMS within 10-20 years of time,31 and around 50% in general MS 
populations needed walking aid around 15 years after onset;42 this interval was 
considerably shorter in patients with PPMS.27,31 Since interferon beta-1b (IFN-β) was 
approved as the first DMT in 1993, a large number of DMTs with various immuno-
modulatory or immune-suppressive mechanisms,43 have improved short-term, and 
most likely long-term prognosis for patients with inflammatory relapsing disease.44 
Along with more high-efficacy DMTs for MS, the term “No Evidence of Disease 
Activity” (NEDA) has been introduced as an ideal outcome for shorter or longer 
periods. The NEDA-3 term includes (i) no relapses, (ii) no disability progression and 
(iii) no MRI activity.45 For non-inflammatory progressive disease, the DMT options 
are still limited, with only one approved drug (ocrelizumab), showing a modest effect 
on disease progression.46 Still, even the most efficacious treatments are not able to 
ultimately halt or cure the disease, and therefore more knowledge about other 
modifiable factors that may alter the disease course is needed.  
1.5 Factors associated with MS risk  
MS is most likely a multifactorial disease, triggered by environmental exposures in 
genetically susceptible individuals. The disease has since the 1970s and for a long time 
been referred to as the “white man’s burden”,47 based on the typical geographical 
distribution and partly lack of research in other ethnic populations. However, a study 
from 2013 observed a higher incidence of MS in Afro-Americans compared to Whites 
in a multiethnic population,48 which may reflect local environmental exposures rather 
than their genetic background. Genetic resistance is likely more relevant in individuals 
of Asian ancestry, where low incidence rates repeatedly have been reported, also 
among migrants.48,49 The next paragraphs will first give an overview of the current 
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knowledge about the main genetic and environmental contributions to the disease, 
before lifestyle-related factors relevant for this thesis will be discussed in more detail.  
1.5.1 Heritability and genetic factors  
In Western countries, the lifetime risk for MS is estimated to 0.1- 0.5% for the general 
population9,50 and 2.5-2.8% among first-degree relatives.50,51 The age-adjusted risk for 
monozygotic twins has been reported to be 17-18%,51,52 which strongly suggests that 
non-genetic factors have an additional and important role in MS susceptibility.52 In the 
1970s, it was recognized that the immune-related human leucocyte antigen (HLA) gene 
cluster53 within the major histocompatibility complex (MHC) on chromosome 6 was 
associated with MS risk.54 A threefold increased risk, and by that the strongest effect, 
has been reported for the specific HLA-DRB1*15:01 gene variant in the HLA class II 
genes54 (important for antigen recognition by T cells22). The genetic research has also 
confirmed the HLA class 1 allele HLA-A*02:01 as a protective gene variant for MS.55  
Genome-wide association studies (GWAS) have now identified more than 200 risk loci 
linked to both adaptive and innate immune cells, of which MHC contains 32 of the 
variants, and one even detected in chromosome X, which all together explains almost 
half of the disease’s heritability.21 Further, potential interactions between genetic risk 
variants and environmental exposures have been discovered,56,57 and epigenetic 
alterations may also contribute to risk modulation in susceptible individuals.20 
1.5.2 Environmental risk factors and their timing in MS  
Migration studies from the 1960s and onwards have provided strong clues for an 
environmental influence on MS risk. Some decades ago, there was more convincing 
evidence for a decrease in MS risk when moving from a high-risk area to a low-risk 
area, than for an increase in MS risk when moving in the opposite direction to a high-
risk area.49 Later, a clearly increased risk was found in a large population-based study 
among immigrants moving from their low-risk country of origin to a high-risk country 
(Denmark).58 The change in risk among first-generation immigrants seems to be age-
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dependent, largely occurring during the first two decades of life.49,58 Also, the risk 
appears to change between generations, with a substantially higher risk observed 
among second-generation compared to first-generation immigrants in high-risk 
countries.58,59 These findings strongly suggest that timing of environmental exposures 
also plays a likely role, with childhood and adolescence being critical ages.60 Even 
exposures in utero and in neonates have been associated with increased MS risk later 
in life.20,61  
Based on early migrant studies and geographical distribution, an infectious agent was 
strongly suspected in MS pathogenesis,47 with age at infection as a likely contributor.49 
In particular, several viruses have been variably linked to the disease,20 but the evidence 
is most consistent for Epstein Barr virus (EBV), especially seropositivity for EBV 
nuclear antigen (EBNA) IgG and infectious mononucleosis (IM),62,63 typically 
occurring in adolescence.63 In a meta-analysis, the overall odds ratio (OR) for MS 
among anti-EBNA seropositive individuals was 4.5 (95% confidence interval (CI) 
3.26-6.11), while for seronegative individuals, the overall OR was 0.13 (95% CI 0.05-
0.33).64 Since EBV seropositivity is highly prevalent in the general population and only 
a few develop MS, complex genetic interactions or alterations are of likely relevance 
in the relationship.20 
Over the years, the associations between several environmental exposures and the risk 
of MS have been explored in numerous studies. An umbrella overview of selected 
meta-analyses reported strongest and least heterogenous evidence across studies for 
EBV and tobacco smoking.62 For vitamin D, higher serum levels of 25-hydroxyvitamin 
D (25(OH)D) have consistently been associated with decreased risk of MS in three 
prospective studies in White populations,65-67 although there is weaker evidence in 
other ethnic groups.65,68 Many studies have also confirmed a likely role for sun 
exposure as well as obesity during childhood and adolescence, on the risk of MS.20,69 
A number of other potential risk factors have also been studied, including dietary 
sodium intake,70 polyunsaturated fatty acids,71 breastfeeding,72 air pollutants,73 organic 
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solvents,74 vaccinations,62 gut microbiota75 and physical activity (PA),76 but it remains 
unclear to which extent they contribute to MS risk. The environmental exposures may 
influence MS pathogenesis through diverse biological pathways (Figure 3).20    
  
Figure 3. Possible biological pathways linking different environmental risk factors to 
MS pathogenesis. Reprinted by permission from the Creative Commons Attribution 




1.6 Lifestyle factors related to MS risk and disease course 
Several of the environmental exposures of likely importance to MS risk have also been 
examined for a potential role in MS disease course.20 Most of these factors can be 
considered as modifiable lifestyle factors, such as levels of vitamin D, obesity, PA, and 
tobacco use/smoking. Thus, gaining more knowledge about these factors may provide 
an opportunity to prevent some cases of MS, and to reduce disease progression in those 
already affected by the disease.  
1.6.1 Sun exposure and vitamin D  
Sun exposure was early suggested as a potential etiological factor for MS, since it, like 
MS prevalence, varies with latitude. In the 1960s, negative correlations between 
average annual hours of sunshine and MS prevalence were found  among U.S. Veterans 
in the Northern hemisphere,77  and in Australian regions in the Southern hemisphere.78 
Both prospective cohorts68,79 and retrospective case-control studies68,80,81 have later 
reported associations between higher sun exposure and lower MS risk in different 
ethnic groups. In addition, indirect measures of sun exposure, such as higher levels of 
outdoor work,82 more actinic skin damage81 and less sunscreen use83 have been 
associated with lower MS risk.  
Sunshine contains ultraviolet B (UVB) radiation, which has likely immunosuppressive 
effects both directly and indirectly through the actions of UVB-induced vitamin D.84,85 
The direct effect may involve upregulation of Tregs and stimulation of anti-
inflammatory cytokines such as interleukin 10 (IL-10) and other mediators.84,86 It is 
therefore biologically plausible that the vitamin D pathway is not the only link between 
UVB exposure and MS, as recently explored in a large Swedish case-control study.87 
At higher latitudes, the strength of UVB radiation varies considerably with season and 
becomes weaker during the winter.88 In MS patients, a latitude-dependent seasonal 
variation in relapse rates have been observed,89 which may reflect a direct effect of 
UVB exposure or factors strongly related to UVB or season, such as vitamin D or 
seasonal infections that may also be influenced by vitamin D status.90  
24 
 
UVB radiation is the main natural source for vitamin D synthesis.91 Several prospective 
studies support a likely role of 25(OH)D levels65-67 or dietary vitamin D intake92,93 on 
MS risk in different geographical areas. In addition, findings from Mendelian 
randomization (MR) studies suggest that low 25(OH)D levels have a causal effect on 
MS risk.94,95 By using single nucleotide polymorphisms (SNPs) that are associated with 
vitamin D levels as an instrumental variable (IV),96 confounding and reverse causation 
is unlikely because SNPs are randomly inherited at conception that temporally precedes 
the outcome/disease (Figure 4).94 However, these MR studies are limited by the 
possibility of pleiotropy, i.e. that the SNPs may affect other pathways leading to the 
outcome, and that the SNPs used in the IV explain 4% or less of the total variance in 
25(OH)D levels.97,98  
 
Figure 4. In MR studies, the use of a genetic instrumental variable (IV) for vitamin D 
levels can minimize confounding and reverse causation that often limit the 
interpretation of an association between vitamin D and MS in observational studies. 
Reprinted by permission from the Creative Commons Attribution-NonCommercial-




Vitamin D has also a likely influence on MS disease activity. Observational studies 
have reported associations between lower vitamin D levels and higher relapse rate99-101 
and more MRI- verified inflammatory activity before102 or during treatment with IFN-
β,101,103  and other DMTs.104 For short-term (< 5 years) disease progression, some 
studies found significant associations between lower 25(OH)D levels and higher EDSS 
scores,101,104 while other studies did not.103,105 For long-term (> 10 years) disease 
progression, the evidence is scarce. One study found that higher baseline 25(OH)D 
levels over 2 years were associated with better cognitive performance in the Paced 
Auditory Serial Addition Test (PASAT) at year 11.106  In another study, 25(OH)D 
levels did not influence long-term EDSS scores, but this study was based on infrequent 
measures of vitamin D once a year during the first 2 years.107  
Randomized controlled trials (RCTs) on vitamin D and disease activity have mostly 
been small and short-lasting, with conflicting results regarding primary outcomes. 
Even the two largest RCTs on high-dose vitamin D3 versus placebo in two IFN-β 
treated populations failed to reach their primary endpoints in the intention-to-treat 
(ITT) population, i.e. NEDA-3 status at 48 weeks (SOLAR study),108 and annual 
relapse rate (ARR) at 96 weeks (CHOLINE study).109 However, in the ITT data of the 
SOLAR study, there was a significant reduction in cumulative new MRI lesions in the 
treatment group, 108 while in the CHOLINE study, analyses among the completers of  
the 96-week trial (69.8%) showed a significant reduction in ARR and less EDSS 
progression in treated patients.109 Why RCTs have failed to confirm a substantial 
treatment effect of high-dose vitamin D when most observational studies have shown 
strong dose-dependent associations between higher 25(OH)D levels and less MS 
disease activity may have several explanations. These include, but are not restricted to, 
unmeasured confounding in observational studies, small sample sizes and short 
duration of RCTs,110 and reverse causation111 (i.e. low vitamin D being a consequence 
of inflammation and/or disease severity).  
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Vitamin D3 is primarily synthesized from UVB exposure of the skin, but additional 
vitamin D3 and D2 can be obtained through dietary intake of fatty fish (D3), vegetable 
sources (D2) and fortified food or supplements.91,112 In the liver, solar and dietary 
vitamin D is converted into 25(OH)D, the main circulating form. This is also the most 
accurate marker for vitamin D because of its long half-life (around 3 weeks), and 
because the levels reflect the available sources.113 In the kidneys, but also in immune 
cells and other cells, 25(OH)D is metabolized into the active compound 1,25-
dihydroxyvitamin D (1,25(OH)2D),91 which has been found to have potent anti-
inflammatory properties, partly through suppression of pro-inflammatory cytokines 
and inhibition of Th1 and Th17 differentiation.84,91 Overall, this modulates the immune 
system into a more tolerable state.  
In the experimental autoimmune encephalomyelitis (EAE) mouse model for MS, 
studies have found a protective effect of 1,25(OH)2D acting on T lymphocytes.114,115 
There is also evidence for a genetic functional role of vitamin D on the MS risk allele 
HLA-DRB1*15 in humans.116 In MS patients, high-dose vitamin D has shown anti-
inflammatory changes on the cytokine level with up-regulation of IL-27, TGF- β1, and 
IL-10, 117 while another study did not detect alterations into a more regulatory profile 
on the lymphocyte level.118 Still, most evidence points towards beneficial anti-
inflammatory effects of vitamin D in MS, where a combination of several vitamin D 
related mechanisms seems plausible.119  
Vitamin D may also be involved in remyelination and neural repair, as shown in 
different animal models of demyelination: In toxic cuprizone mouse models, reduced 
white matter demyelination120 and less axonal loss121 was observed after vitamin D3 
supplementation. In an EAE model, injection of 1,25(OH)2D elevated the number of 
oligodendrocyte precursor cells and oligodendrocytes in demyelinating lesions in 
CNS.122 Lastly, in a recent study with lysolecithin-induced demyelination in rats, 
dietary vitamin D3 supplements promoted oligodendrocyte differentiation and 
neuroblast migration to the demyelinated lesion site.123  
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From a bone-health perspective, 25(OH)D levels <75 nmol/L is considered 
insufficient,124 while vitamin D deficiency is generally defined as 25(OH)D levels <50 
nmol/L.125,126 The levels can vary considerably through the year, along with seasonal 
variations of UVB-induced vitamin D synthesis.127 Residents at latitudes above 50° 
north or south, such as in Norway, are more prone to vitamin D deficiency during the 
winter months, since the weak UVB radiation leads to a “vitamin D winter” period with 
nearly absent cutaneous vitamin D production (Figure 5).128 Thus, dietary sources of 
vitamin D become more important during this time of the year.  
 
Figure 5. Daily vitamin D production (in hours) is dependent on latitude: The black 
area indicates the “vitamin D winter” at high latitudes when UVB exposure (from a 
clear atmosphere) is too weak for vitamin D production. Reprinted by permission from 




1.6.2 Body size and obesity 
Obesity is currently considered an epidemic among both children and adults in most 
parts of the world.129 The World Health Organization (WHO) defines overweight as 
body mass index (BMI) 25-29.9 kg/m2, and obesity as BMI ≥ 30 kg/m2.129 Since 
childhood and adolescence appear to be critical ages for MS susceptibility,60 and 
obesity has been associated with lower levels of circulating vitamin D,130,131 Munger 
and colleagues explored the association between obesity at age 18 and 20 years, and 
the risk of MS in two large cohorts of American female nurses (Nurses Health studies 
(NHS) I and II). In this study, both BMI ≥ 30 kg/m2 at age 18 years and a large self-
reported body size at age 20 years were associated with a 2-fold increased risk of MS, 
compared to a reference “normal weight” value.132 Similar results were found for 
overweight young men in a Norwegian cohort,76 and for both male and females at age 
20 years in a Swedish population-based case-control study and in a pediatric cohort in 
Germany.133,134 However, the association may be stronger among females than men, as 
reported in three other studies exploring the association between obesity and 
pediatric135 and adult-onset MS.136,137  
 
Hedström and colleagues showed that the risk may be driven by adolescence rather 
than childhood (age < 10 years) obesity in a Swedish population.138 In case-control data 
from Sweden and California, striking interactions between HLA risk variants and 
overweight/obesity (BMI ≥ 27kg/m2) in the 20s were seen, with ORs > 13 for 
individuals of greatest genetic MS susceptibility (positive HLA-DRB1*15 and 
negative protective HLA-A*02 status).56 A likely causative role for high BMI on MS 
risk has been demonstrated through MR studies,139,140 after adjusting for MS 
susceptible risk alleles,140 and also for genetically determined childhood BMI.141 Even 
though MR is a useful tool to investigate the causality of an association, the SNPs used 
in these MR analyses account for less than 6% of the total variance of BMI.142 
Therefore, the total effect of all BMI-related factors on MS risk cannot be evaluated 
from MR studies. 
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Obesity may also be relevant after disease onset. Two studies have suggested that high 
BMI reduces therapy response on injectible DMTs: In a Norwegian adult MS 
population, a lower proportion of overweight (BMI > 25 kg/m2) patients achieved 
NEDA-3 during IFN-β treatment (13% versus 26% in the normal-weight group),143 and 
in a large German cohort of pediatric MS patients, obese (BMI > 97th percentile) 
children had more relapses on low-potent injectable DMTs, and more commonly used 
high-potent DMTs.134 Further, higher BMI has been associated with reduced brain 
volume, including grey matter loss,144 the latter being a predictor for disability 
progression.145 Also, comorbidities related to obesity146, such as hypertension, 
dyslipidemia and other vascular conditions, have been associated with faster disability 
progression in MS.147-149 However, evidence for a direct relationship between obesity 
and disability has been conflicting. Several cross-sectional studies reported 
associations between disability scores and general or abdominal obesity,150,151 and in a 
CIS population148 and a small MS population,152 higher BMI was associated with short-
term disease activity and EDSS disability progression, also irrespective of therapy.152 
Contrary to these results, other studies observed no significant associations between 
BMI and cross-sectional EDSS scores153 or self-reported 154 or objective verified 
disability progression.155 In general, MS populations tend to be leaner than their age-
matched controls, as shown in several studies.156-158  
Vitamin D levels have been proposed as a potential biological link between BMI and 
MS. Vitamin D deficiency is common among obese children and adults,159 likely due 
to decreased bioavailability of vitamin D from cutaneous and dietary sources,160 and 
greater total body adipose stores for this fat-soluble vitamin.161 However, evidence 
from recent MR studies has demonstrated causal effects of BMI-associated SNPs on 
MS risk either independent of,162 or with only minor attributions from genetically 
determined vitamin D levels, suggesting that other factors than vitamin D can be more 
relevant for the association between BMI and MS.  
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These other factors may be related to a chronic inflammatory state observed in obese 
individuals.163 Obesity creates pathogenic adipose tissue with infiltration of activated 
innate and adaptive immune cells and dysregulated secretion of pro-inflammatory 
substances referred to as adipokines (Figure 6), including tumor necrosis factor 
(TNF), leptin and IL-6.164 Specifically, the appetite-controlling hormone leptin has 
been investigated for a role in MS, since it has receptors in the CNS,165 and has been 
shown to polarize T cells into a pro-inflammatory Th1 phenotype,164 which are 
considered central in MS pathogenesis.19 Although leptin-deficient mice did not 
develop symptoms of EAE,166 the importance of leptin on MS in humans is less clear: 
One case-control study suggested that leptin may be a risk factor for MS, but the 
analyses were not adjusted for BMI.167 In contrast to this, a prospective study found 
no association between leptin levels and clinical or MRI disease activity over 2 
years,168 and no causal effect of genetic estimates of leptin on MS risk was observed 
in a recent MR study.169  
 
Figure 6. Pathophysiological events that may contribute to obesity-associated 
neuroinflammation. Reprinted by permission from Springer International 
Publishing AG: Obesity and Brain Function, Advances in Neurobiology, vol 19, 




Further, dietary aspects of obesity have been examined for a role in MS: In mouse 
models, a more severe EAE was observed in mice on a high-fat diet, possibly induced 
by increased immune cell infiltration of the CNS,171  and expansion of pro-
inflammatory Th17 cell pools.172 On the other hand, chronic calorie restriction was 
found to promote anti-inflammatory mechanisms and attenuated EAE.173 In MS 
patients, beneficial effects were reported for the low-fat, long-lasting, “Swank diet”,174 
but this study had many limitations, and interventional RCTs of good quality are 
needed.175 A prospective study among 219 pediatric patients with MS showed that each 
10% increase in saturated fat intake was associated with a threefold increased risk of a 
relapse in a model also adjusting for BMI and vitamin D levels.176 Interestingly, 
ceramide species partly derived from saturated dietary fat may be relevant for DNA 
alterations and activation of monocytes in obese MS patients.152 Overall, the link 
between BMI and MS appears to be a puzzle of many immunological pathways and 
mediators, and we still need more studies to fully determine the role of high BMI on 
disease activity and disease progression.    
1.6.3 Physical activity  
It is well-known that regular PA provides substantial health benefits, likely reduces  
all-cause mortality,177 and has been found to decrease the risk of a number of 
conditions, including coronary heart disease,178 diabetes type II,179 various cancers,180 
Alzheimer’s disease181, and several autoimmune diseases.182 In MS, it may also modify 
the disease risk and improve fatigue, mobility and quality of life,182 although evidence 
for a direct effect on disease activity and progression is less clear.183   
In animal models, a significantly delayed onset of chronic-relapsing EAE was observed 
in exercised rats, 184 while another study among voluntarily exercised mice showed an 
attenuated course of EAE.185 In humans, only a few studies have investigated the 
association between PA and the risk of MS. In a case-control study, newly diagnosed 
MS cases reported to be more physically active than their controls in the 1-year period 
immediately prior to the diagnosis of MS.186 However, this study was limited by the 
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subjective, qualitative nature of the PA question, and that only PA during a short time 
period before diagnosis was assessed.186 Two large registry-based cohort studies 
among Swedish and Norwegian 18-19 year-old men eligible for Military Service found 
that better physical fitness assessed by a cycle ergonomic test in Sweden and a maximal 
endurance running test in Norway, was associated with significantly lower MS risk, 
also after adjusting for BMI.76,187 In Norway, the relative risk (RR) was 0.69 (p-trend= 
0.003) for the most fit compared to the least fit men. The estimates remained similar 
after excluding cases with disease onset within 10 years after conscription, arguing 
against any premorbid symptoms (i.e. reverse causation) explaining the association.76 
Dorans and colleagues examined whether the risk of MS in the female cohorts of NHS 
I and II was influenced by recent or cumulative amounts of PA at adult ages, or by 
recalled early life PA at ages 12-22 years. They found a weak association between 
higher categories of adult PA and lower MS risk, but the trend disappeared in lagged 
analyses with exclusion of the first 6 years of follow-up after reported PA. For PA 
during adolescence, no consistent associations between different measures of PA and 
MS risk were found.188     
MS patients are in general less physically active than non-diseased individuals.189 
Engaging in different sports and physical activities appear to be favourable for muscle 
strength, mobility and fatigue,190,191 but it remains unclear whether PA has beneficial 
effects on the disease itself. In general, interventions of various exercise modalities of 
until 6 months duration have not shown any clear associations with clinical disability 
scores.183 At least, no harmful effects of exercise on MS disease, including no increased 
relapse rates, have been observed.191,192    
A possible link between higher PA and lower risk of MS may be related to 
immunomodulatory actions of PA. While immediate exercise produces an acute-phase 
inflammatory response,193 higher levels of PA over some time is associated with 
significantly reduced levels of CRP and a decrease in pro-inflammatory cytokine 
production in adipose, skeletal and vascular tissue.194 In addition, endurance training is 
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associated with higher levels of anti-inflammatory IL-10 and Treg cells.195 Cortisol and 
catecholamines are released during acute bouts of exercise of some intensity,196 and 
both substances have anti-inflammatory properties: Cortisol has been found to suppress 
IL-12 and TNF-α and may thus inhibit activation of Th1 cells, while catecholamines 
may create a shift towards an anti-inflammatory Th2 profile by suppressing IL-12 and 
induce IL-10 production.197,198 Altogether, these favourable inflammatory changes can 
potentially prevent immune-mediated events which eventually trigger MS.  
1.6.4 Smoking and tobacco use   
Tobacco smoking has consistently been associated with increased risk of MS in 
different populations and studies, with the evidence presented in several meta-analyses 
and reviews during the last decade.62,199 Smoking is associated with approximately 1.5 
times higher MS risk199 and there is evidence for a dose-response relationship.200,201 
Past smoking,200,201 passive smoking202,203, and indirect measures of smoking, such as 
serum cotinine levels,203 a nicotine metabolite,204 have also been associated with 
increased risk of MS. However, studies on nicotine-containing oral snuff use and MS 
risk have reported no205 or even a possible protective effect for MS,201,206 indicating 
that nicotine may not be the main driver of the association between tobacco smoke and 
MS. Further, interactions between smoking and HLA risk gene variants for MS have 
been observed in several populations,207 which strengthens a causal role for smoke in 
MS, since inherited genes in smokers and non-smokers are not affected by reverse 
causation, and genes are unlikely to regulate smoking behaviour.208   
In MS disease, some studies,209-211 but not others,212-214 have observed faster disease 
progression and earlier transition to SPMS among smokers and ever-smokers 
compared to never-smokers. The rate of disease progression seems to be dependent on 
the number of pack-years,215 and conversion to SPMS appears to be delayed by 
smoking cessation. 216  In addition, smoking has been associated with higher MRI 
lesion load and greater brain atrophy compared to never-smokers.217 The evidence is 
more conflicting for smoking and inflammatory disease activity. Two studies based on 
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cotinine levels reported no association between tobacco use and subsequent relapses or 
MRI activity,214,218 while two Danish cohort studies showed a significant association 
between cigarette smoking and higher relapse rate in patients treated with IFN-β219 and 
natalizumab,220 respectively.  
Since a burning cigarette generates more than 4500 chemical compounds,221 the 
biological links between smoking and MS are likely diverse and complex. Potential 
explanations include demyelination caused by chronic cyanide intoxication,222 
dysregulation of the blood-brain barrier by nicotine223 and other compounds, different 
inflammatory effects, and neurotoxic actions of nitric oxide (NO).221 Some 
inflammatory effects may be mediated by down-regulation of indoleamine 2,3-
dioxygenase activity in T cells in combination with activation of the renin-angiotensin 
system, which in cells isolated from smoking MS patients led to increased production 
of pro-inflammatory cytokines and reduced numbers of Treg cells.224 Since there is no 
evidence of an increased risk of MS among oral snuff users, inflammatory alterations 
of the lung tissue from cigarette smoking may be an important mechanism. 207 Of note, 
it has been shown that the lung tissue has the ability to stimulate and activate T cells 
and give them CNS migratory properties.225 Lastly, experimental rat models have 
demonstrated  that NO can cause axonal damage and degeneration,226 especially in 
demyelinated axons,227 and thus be a promoter for faster disability progression in 
smokers with MS.  
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2. Study rationale and objectives 
2.1 Rationale  
During decades of epidemiological research, it has been recognized that modifiable 
environmental factors are of likely importance for both MS risk and disease course. 
Since 1993, an increasing number of DMTs have become available,43 but none of them 
have proven to cure the disease. It is therefore important to gain more knowledge about 
factors that can reduce the risk of MS or disease progression in MS. For MS risk, a 
large body of evidence has established EBV, smoking and low vitamin D as likely risk 
factors,228 whereas less research regarding a potential role for obesity and PA had been 
conducted prior to this thesis. For MS disease course, low vitamin D110 and 
obesity143,148 have been associated with short-term inflammatory activity, but there is 
limited evidence on the potential long-term effects of these factors. Smoking has been 
associated with more rapid disease progression and earlier transition to SPMS in 
many,209-211,216 but not all studies,212-214 and the findings have been mostly based on 
self-reported measures. In this thesis, the overall aim was to explore the influence of 
lifestyle factors on both MS risk and disease progression, and by this provide better 
evidence-based recommendations on what may and may not prevent MS disease and 
reduce long-term progression.  
2.2 Main objectives  
The main objectives of this thesis were:  
1. To examine whether self-reported body size at different ages during childhood, 
adolescence and young adulthood were associated with MS risk, and if so, 




2. To examine whether higher average amounts of light and vigorous PA during 
adolescence (13-19 years) were associated with lower risk of MS, and to 
evaluate the role of possible reverse causation.  
 
3. To examine whether repeated measures (over two years) of serum levels of 
vitamin D, cotinine, and BMI were associated with long-term (10 years) 
disability progression in MS; and for vitamin D, to further determine the 











3. Materials and methods 
3.1 Paper 1 and 2: The EnvIMS study 
3.1.1 The study design 
The Environmental Risk Factors in Multiple Sclerosis (EnvIMS) study is a large 
population-based multinational case-control study designed to explore associations 
between age-specific environmental exposures selected from previous etiological MS 
research, and MS risk.229 Disease onset among cases was defined as year of first 
reported MS symptoms, since symptoms may precede diagnosis by several years. The 
study was conducted in several European countries (Norway, Sweden, Italy and Serbia) 
mainly between 2009 and 2011, and later in Canada (2012-2013). All data was obtained 
through a mailed questionnaire, the EnvIMS-Q. The mailing package included an 
information brochure, the EnvIMS-Q, and a prepaid return envelope. If no response 
was received after 4-6 weeks, a second mailing was performed. The EnvIMS design 
made it possible to evaluate the consistency of associations between exposures and MS 
risk across different geographical areas, and to investigate interactions between 
selected environmental risk factors.  
3.1.2 The study population  
The studies based on the EnvIMS study in this thesis used available data from cases 
and matched controls in Norway and Italy (Paper 1 and 2), and also Sweden (Paper 2). 
Overall, cases were included if they (i) had a diagnosis of MS verified by the Poser33 
or McDonald criteria,35,230 (ii) were ≥18 years of age, and (iii) had a symptom onset of 
≤ 10 years at the time of study invitation. Based on power and sample size calculations 
before the study start, an enrollment of four controls per case was planned. The cases 
were selected from national or regional MS registries or databases, while population-
based sources were used to provide controls matched on sex, age (within 5 years), and 
geographical residence. The eligible controls were cross-checked against the sources 
of cases to ensure that no controls were diagnosed with MS.  
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In Norway, cases were recruited from the whole country through the Norwegian MS 
Registry and Biobank.231 Norway has a crude national prevalence of around 200 per 
100 000.232 A total of 1368 eligible cases were invited to the study, and 953 (70%) 
consented to participate. For each case, four matched controls were randomly selected 
from the Norwegian National Registry,233 which includes core demographic 
information about all residents in Norway. A total of 1717 out of 4728 (36%) invited 
controls responded.  
In Italy, the cases were recruited from the island of Sardinia, the province of Ferrara, 
and the Republic of San Marino (a little country surrounded by Italy). These areas have 
a high estimated prevalence of MS, with recently updated crude prevalence rates of 
342 per 100 000 in Sardinia,234 195 per 100 000 in Ferrara,235 and 204 per 100 000 in 
the Republic of San Marino.236 In these regions, the cases were selected from regional 
MS registries, and 707 out of 1692 (42%) invited cases responded. The controls were 
randomly drawn from regional population-based registries, and the response rate 
among the controls was 21% (1333 among 6414 eligible controls).  
In Sweden, the study population comprised cases and controls from the counties of 
Östergötland and Värmland. In 2011, the nationwide prevalence rate was around 190 
per 100 000.237 The Swedish MS Registry238 provided 381 eligible cases for this study, 
of whom 259 (68%) consented to participate. However, 244 were finally included in 
the analyses, since 14 had missing on age of onset and one had more than 10 years 
disease duration. Matched controls were randomly selected from the Swedish 
Population Register,239 and from 1734 invited controls, 644 (37.1%) were available for 
the analyses.  
3.1.3 The EnvIMS Questionnaire  
The EnvIMS-Q was a 6-page self-administered postal questionnaire divided in 
different sections of exposures. It was first developed in English, and then translated 
into the participating countries’ own languages. The content of the EnvIMS-Q was 
identical for cases and controls and included main “core questions” similar for all 
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countries on environmental and lifestyle factors that covered childhood infections 
(including IM), vitamin D sources (outdoor activity/sun exposure, dietary habits and 
supplementation), tobacco smoking and passive smoking habits, body size, and PA. 
The EnvIMS-Q has shown cross-cultural feasibility, acceptability and reliability 
among both cases and controls.240   
For the study in Paper 1, recall on past body sizes was facilitated by means of the visual 
Stunkard’s figure rating scale (FRS)241 which depicts nine female or male body 
silhouettes ranging from 1 (=leanest) to 9 (= most obese) (Figure 7). The participants 
were asked to report the body silhouette that best reflected their own body size every 
five years from age 5 years until 30 years, and at current age (at time of the study). In 
addition, they also reported their current height and weight, to validate their perceived 
body size.  
 
Figure 7. Stunkard’s Figure Rating scale241 with corresponding current mean BMI 
based on reported height and weight for females and males in the EnvIMS study (cases 
and controls combined). Reprinted by permission from SAGE publications: Multiple 




Other relevant covariates included smoking habits (smokers, ever-smokers and non-
smokers) and outdoor activity during summer at corresponding ages as reported body 
silhouettes, as a marker for sun exposure/vitamin D. The frequency of outdoor activity 
was reported on a four-point scale (1= not that often, 2= reasonably often, 3= quite 
often and 4= virtually all the time). Data on outdoor activity during the winter was 
omitted in the analyses, since UVB radiation is weaker and UVB-induced vitamin D 
synthesis is minimal in the winter months at latitudes above 60° where Norway is 
situated.128 
For the study in Paper 2, one section in the EnvIMS-Q provided data on adolescent PA. 
The participants reported their average weekly amount of light PA (i.e. no increased 
respiratory rate or perspiration) and vigorous PA (i.e. increased respiratory rate and 
perspiration) between age 13-19 years on a four-point scale (“none,” “less than 1,” “1–
2,” and “3 or more” hours per week). Other covariates obtained from the the EnvIMS-
Q were smoking (ever-never), IM (ever-never), cumulative outdoor activity during 
summer in adolescence, and body size at age 15 years (defined by Stunkard’s FRS as 
previously described).  
3.1.4 Ethical considerations and approvals  
The EnvIMS study was approved by local ethical committees at each site.229 Each 
participant was de-identified by a unique numerical ID printed on the EnvIMS-Q pages, 
and return of the questionnaire was considered informed consent. 
3.1.5 Statistical analyses  
To ensure that the cases and controls had the same exposure opportunities, the controls 
were assigned an index age corresponding to the age of disease onset for a matching 
case. Thus, exposures reported after the index age/age of onset were not considered as 
exposure and were excluded in the analyses. Logistic regression models were used to 
estimate the ORs with 95% CI for associations between the exposures and the risk of 
MS. The OR is a risk estimate that can be compared with the RR for diseases with a 
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low incidence in a population, such as MS.242 A p-value for trend across categories of 
body size and PA was calculated by including these exposures as continuous variables 
in the models. 
In Paper 1, the age-specific body size was either included as a categorical or a 
continuous variable in different regression models, since a chi-square goodness-of-fit 
deviance test showed no better fit of the model with body size as a categorical versus 
a continuous variable, suggesting a dose-response relationship. In the main analyses, 
the body silhouette 3 was chosen as the reference, since this corresponded to a “normal” 
current BMI according to WHO definitions129 in the study population, and also allowed 
for comparison with a large cohort study on body sizes based on Stunkard’s FRS, and 
MS risk.132 The body sizes 6-9 were combined into a “large body size” category to 
ensure sufficient numbers in each category. We stratified on sex and adjusted for age 
groups, summer outdoor activity, and smoking habits at the same age as reported body 
size.  
Thereafter, we performed similar analyses with body size as a continuous variable to 
estimate the OR for MS per one unit increase in body size. In these models, we adjusted 
for sex, since there was no significant interaction between sex and body size on the 
multiplicative scale. Finally, to explore whether there was a stronger association 
between obesity and MS risk closer to disease onset, we performed time-lag analyses 
of reported body sizes 1-15 years prior to onset by converting the age-specific body 
sizes into “year-before-onset” body sizes, as further described in Paper 1. For instance, 
if the age of onset was 24, then the participants’ reported body size at age 20 and at age 
15 represented their body sizes four and nine years before onset, respectively.  
In Paper 2 we did both pooled analyses for Norway, Italy and Sweden, and country-
specific analyses to assess any geographical differences. Light and vigorous PA were 
categorized into three levels; “< 1 hour”, “1-2 hours, and “≥3 hours” of average weekly 
activity. The lowest level (“< 1 hour”) was used as the reference in the logistic 
regression analyses. The main models were all adjusted for sex and age-groups, and in 
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multivariable models, we additionally adjusted for potential confounders, including 
level of summer outdoor activity during adolescence, IM, smoking, and body size at 
age 15 years. Further, the pooled analyses were stratified on sex to examine whether 
an association differed between males and females, and we also ran a sensitivity 
analysis where we excluded participants with an index age/age of onset of 30 years or 
less to evaluate the possibility of reverse causation.  
The statistical analyses were performed in IBM SPSS Statistics, and the level of 
significance was set to < 0.05.  
3.2 Paper 3: The OFAMS baseline and follow-up study 
3.2.1 The study design and study population 
The study in Paper 3 was based on data from a Norwegian cohort of MS patients who 
participated in the OFAMS (Omega-3 Fatty Acids in MS) study,243 and then in the 
OFAMS 10-year follow-up study.  
The OFAMS baseline study was a randomized, placebo-controlled study of marine 
omega-3 fatty acids in MS conducted at 13 neurological centers in Norway between 
2004 and 2008. A detailed description of the study is reported elsewhere.243 A total of 
92 patients aged 18-55 years with a diagnosis of RRMS were screened for the study, 
of whom 88 completed more than a year. During the study period of 24 months, 
frequent clinical examinations, MRI scans of the brain and blood samples were done. 
IFN-β was given subcutaneously to the whole population during the last 18 months. 
The blood samples were cryopreserved at -80°C at the Neurological Department, 
Haukeland University Hospital, Bergen, for later within-study and post-study analyses. 
Overall, the OFAMS study failed to meet its primary endpoint of an effect of omega-3 
in MS,243 but later observational studies based on available OFAMS data and serum 
analyses showed an association between 25(OH)D levels and MRI activity before 
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initiation of IFN-β,102 and more disease activity among overweight and obese 
individuals after initiation of IFN-β.143  
About 10 years later, the OFAMS 10-year follow-up study was organized and 
coordinated by the author of this thesis (K. Wesnes). The OFAMS patients still alive 
(N=91) were invited to this study, and 85 (93.4%) gave their informed consent. Data 
collection was performed during 2017 by neurologists and study site personnel at the 
13 collaborating neurological centers. K. Wesnes examined the OFAMS patients at St. 
Olav’s University Hospital, Trondheim (N=12) and at Telemark Hospital Trust, Skien 
(N=7). The study included a clinical visit with an assessment of the EDSS score,30 the 
MS Functional Composite244 (25-Foot Walk test, 9-Hole Peg test and PASAT), the oral 
Symbol Digit Modalities Test, 245 self-administered questionnaires on fatigue (Fatigue 
Severity Scale), mental health (Hospital Anxiety and Depression Scale), and lifestyle 
habits during the last 10 years (questionnaire developed for this study). In addition, an 
MRI scan of the brain, as well as blood samples for routine analyses and 
cryopreservation at -80°C for later studies, were performed. Available and de-
identified data with unique study-IDs was plotted in a data set by Dr. Wesnes.  
3.2.2 Lifestyle exposures in the OFAMS baseline study                          
For the study in Paper 3, 25(OH)D levels and cotinine levels were already measured as 
part of previous studies within the OFAMS study population.102,213 The 25(OH)D levels 
were simultaneously analysed in nine defrosted blood samples collected at baseline 
visit, month 1, 3, 6, 7, 9, 12, 18, and 24 with a radioimmunoassay kit at the Department 
of Medical Biochemistry, St. Olav’s hospital, Trondheim, Norway.102 Cotinine levels 
were simultaneously analysed in five defrosted blood samples from baseline visit, 
month 6, 12, 18, and 24 with liquid chromatography-tandem mass spectrometry at 
Bevital AS, Bergen, Norway.213 Participants with cotinine levels >85 nmol/L in ≥ 60% 
of the samples during the OFAMS baseline study were classified as tobacco users.  
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BMI at each visit was calculated from the participants’ reported height (in meters) and 
weight (in kg) at screening, and then at baseline visit, month 1, 3, 6, 7, 9, 12, 18, and 
24 (N=10).  
3.2.3 Outcome measure: EDSS progression  
For Paper 3, we decided to focus on disability progression based on the EDSS score, 
since this score is globally accepted and easy to interpret and compare with other 
studies. The EDSS score was assessed at baseline visit, month 6, 12, 18, and 24 in the 
baseline study, and then repeated once at the 10-year follow-up visit (Figure 8). The 
EDSS progression was defined as the change in EDSS between the last score in the 
baseline study and the new score at follow-up. The majority had their last EDSS score 
at month 24, but one patient had the last score at month 12 and one patient at month 
18.  
Figure 8. A timeline that illustrates the frequency of relevant exposures and outcome 




3.2.4 Missing data                                                                                            
For the study in Paper 3, we first included 88 patients who completed more than a year 
in the baseline study. Since eight of these had missing on EDSS scores in the follow-
up study, our study population finally comprised 80 patients (90.9%) available for the 
analyses. 
3.2.5 Ethical considerations and approvals 
Both studies were approved by the Regional Committee for Medical and Health 
Research Ethics in Western Norway. The participants received information and signed 
informed consent prior to inclusion. 
3.2.6 Statistical analyses 
Prior to the analyses, the crude 25(OH)D levels were seasonally adjusted by a sine 
function adapted to the 25(OH)D levels in the baseline study.246 Then, a mean value 
for seasonally adjusted 25(OH)D, cotinine and BMI for each patient were calculated, 
based on all available measures during the baseline period. We used linear regression 
to estimate the association between the separate lifestyle factors and the change in 
EDSS score during follow-up. We included the exposures as standardised continuous 
variables (mean=0, standard deviation (SD)=1) to maximize power, and in separate 
models as categorical variables (quartiles) to explore possible nonlinear associations. 
A p-value for linear trend across the quartiles was estimated by including the median 
value for each quartile as a continuous variable in the regression model. All models 
were adjusted for sex, age and baseline EDSS score (=last EDSS score in the baseline 
study). We further mutually adjusted for all three lifestyle factors, MRI inflammatory 
activity and annual relapse rate during the baseline study, disease duration from year 
of diagnosis to follow-up, and the use of DMT at follow-up. We also adjusted for a 
cumulative sun exposure variable based on recalled summer outdoor activity during 
the follow-up period, but as this only had a minor influence on the estimates, the 
variable was omitted in the final models.   
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For 25(OH)D levels, we performed additional analyses as well: First, we explored 
whether there was a non-linear relationship between the seasonally adjusted values, 
and the increase in EDSS score by fitting a Locally Estimated Scatterplot Smoothing 
(LOESS) curve to the data. Second, we investigated the seasonal influence on the 
association between 25(OH)D and EDSS progression by dichotomizing the patient’s 
mean 25(OH)D levels per season into a “< median” and “≥ median” variable. The 
seasons were summer (June-August), fall (September-November), winter (December-
February) and spring (March-May). The dichotomized seasonal variables were then 
included as independent variables in linear regression models adjusted for sex, age and 
baseline EDSS score, with EDSS change between baseline and follow-up as the 
outcome variable.  
 
The statistical analyses were done in IBM SPSS Statistics, while the plots were made 
















3.3. An overview of the Papers 
This table gives a brief overview of the Papers’ topics, study population, main  




Papers Topic Study population Main statistical 
methods 
Covariates  
Paper 1 Body size and the 




Norway: 953 cases, 
1717 controls  
Italy: 707 cases, 1333 
controls 
Logistic regression  
Exposure: Body size 
modelled as a 
categorical and 
continuous variable  
 
Outcome: Risk of MS. 
  
Separate analyses for 
Norway and Italy.  
Depending on model:  
- Sex  
- Age groups  
- Smoking status  
- Summer outdoor 
activity at 
corresponding ages 
Paper 2 Adolescent 
physical activity 




Norway: 953 cases, 
1717 controls 
Italy: 707 cases, 1333 
controls 
Sweden: 244 cases, 644 
controls 
Logistic regression  
Exposure: Physical 
activity modelled as a 
categorical variable in all 
analyses.  
 
Outcome: Risk of MS. 
 
Pooled and country-wise 
analyses.  
Depending on model:  
- Sex  
- Age groups  
- IM  
- Summer outdoor  
activity during 
adolescence  
- Smoking status 
- Body size at age 15 
years  
Paper 3 Lifestyle factors 
(vitamin D, 
tobacco use, BMI) 
and long-term 
disability 




80 MS patients with 
available EDSS scores 
from OFAMS baseline 




adjusted 25(OH)D levels, 
cotinine levels, and BMI 





Outcome: Change in 
EDSS score between the 
last score in the baseline 
study and the score at 
follow-up.   
 
Depending on model:  
- Sex  
- Age  
- Mutually 
adjustments for all 
three lifestyle 
exposures 
- Disease duration  
- DMT at follow-up 
- Cumulative MRI 
activity and   
annual relapse rate 
during baseline 
study 
BMI: Body mass index, EDSS: Expanded Disability Status Scale, 25(OH)D: 25-hydroxyvitamin D, IM: Infectious 




4.1 Paper 1  
“Body size and the risk of multiple sclerosis in Norway and Italy: The 
EnvIMS study” 
In this study, we found that a large body size (Stunkard’s silhouettes 6-9) in Norway 
was associated with an increased risk of MS compared to body size 3 with a significant 
p-trend from age 15 to age 25 years. The strongest association was found at age 25 for 
both males and females, (OR 2.21 (95% CI: 1.09-4.46) for men and OR 1.43 (95% CI: 
0.90-2.27) for women). Further adjusting for smoking and summer outdoor activity 
gave similar results. In Italy, no clear trend in these analyses was found. However, a 
potential protective effect of body size 1 and 2 compared to body size 3 was found in 
both countries.  
In the sex-adjusted analyses with body size as a continuous variable, each one- unit 
increase in body size was associated with a significantly increased risk of MS from age 
10 until age 30 years in Norway, which was most pronounced at age 25. In Italy a 
similar, but non-significant, trend was found until age 20. Finally, we observed that a 
large body size was associated with increased risk of MS during the whole 15-year 
period before MS onset in Norway, but not in Italy. After disease onset, an inverse 
association was seen in both countries, with controls having larger body sizes relative 





4.2 Paper 2  
“Physical activity is associated with a decreased multiple sclerosis risk: 
The EnvIMS study”                                                                          
In this study, higher levels of vigorous PA in the pooled analyses for all countries were 
associated with a decreased risk of MS, with a significant p-trend across the categories. 
The age- and sex-adjusted OR for the highest level (≥3 hours of PA per week) was 0.74 
(95% CI 0.63-0.87) compared to the lowest level (< 1 hour per week). Further 
adjustment for additional covariates gave similar results. The same trend was found in 
separate analyses for each country, although not all p-trends were significant in 
multivariable analyses. The association was stronger for women than men, but the 
difference was not significant when testing for interaction between sex and vigorous 
PA on the multiplicative scale (p= 0.58). In a sensitivity analysis in the pooled data 
with exclusion of participants with an age of onset/index age of ≤ 30 years, a similar 
age- and sex-adjusted OR for the highest versus the lowest level of vigorous PA was 
found (OR 0.79, 95% CI: 0.65-0.96 versus OR 0.74, 95% CI: 0.63-0.87 for all 
participants).  
4.3 Paper 3 
“Low vitamin D, but not tobacco use or high BMI, is associated with long-
term disability progression in multiple sclerosis”   
 
In this study, higher seasonally adjusted 25(OH)D levels during the OFAMS baseline 
study were significantly associated with reduced 10-year EDSS progression in the 
continuous model (per 1 SD increase) as well as in the categorical model (quartiles). 
Adjustment for potential confounders in the models did not attenuate the association. 
During the baseline period, 25(OH)D levels were lowest in March and highest in 
August. In the analyses with dichotomized 25(OH)D levels per season, low 25(OH)D 
levels during early spring appeared to be the main driver of the association, also after 
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mutually adjusting for the other seasonal levels. Finally, a fitted LOESS-curve to the 
measures showed a ceiling effect for seasonally adjusted 25(OH)D levels around 80 
nmol/L, as little additional benefits on disease progression for higher 25(OH)D levels 
were seen.  
 
For tobacco use (cotinine levels), no clear association with long-term disability 
progression was observed, neither in the continuous model, nor in the categorical 
model. For BMI, no significant association was found, but we observed a trend towards 





5. Discussion  
5.1 Contribution of the findings 
5.1.1 Paper 1 
Our study on body size and the risk of MS was among the first to demonstrate that the 
observed association is evident at young adult ages beyond adolescence,132,133 and in 
both men and women.132,135 Further, we could explore associations between reported 
body sizes at different ages from early childhood (age 5 years) until young adulthood 
(age 30 years), and also assess whether a lean body size might be of relevance. The 
EnvIMS design made it possible to compare results from two different geographical 
areas, and to adjust for relevant environmental exposures at corresponding ages that 
could confound the results. Since we had information on reported body sizes in the 
years before and after MS onset, we could also evaluate (i) whether an association 
between body size and MS risk could depend on the time interval before diagnosis, and 
(ii) whether the disease itself changed the body composition of MS cases relative to 
controls. Contrary to a similar analysis in the female cohorts of NHS I and II,132 our 
data showed that a large(r) body size in Norway was associated with an increased risk 
of MS during at least 15 years prior to diagnosis. However, in our analyses, we only 
included reported body sizes at likely susceptible ages up to 30 years (with the latest 
MS onset at age 45 years), while the NHS I and II included baseline information on 
weight and height at any age before MS diagnosis over the whole age spectre.132 On 
the other hand, both studies showed a decline in weight among cases relative to controls 
after disease onset, consistent with other studies that have reported lower BMI in MS 
populations compared to the general population.132,157  
In the EnvIMS data, we only observed a significant association between a large body 
size and MS risk in Norway, but not in Italy. There could be several explanations for 
this finding. First, obese Italians may differ from obese Norwegians with regard to 
dietary factors or other lifestyle behaviours, or their genetic profile may include 
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protective variants interacting with BMI-related risk genes.139 Second, the current 
mean BMI was significantly lower among both cases and controls in the Italian 
compared to the Norwegian study population, which could have influenced the results. 
Nevertheless, the findings in Norway are consistent with observations in prospective 
cohort studies suggesting an increased risk of MS among overweight and obese 
teenagers in California,135 young men (18-19 years) in Norway76 and young women 
(18-20 years) in USA.132 The potential biological mechanisms explaining this 
relationship could be related to lower vitamin D levels among overweight 
individuals,159 or perhaps more likely to chronic inflammatory changes in obese 
individuals,163,170 as discussed in the introduction of this thesis.  
5.1.2 Paper 2 
PA and exercise have been mostly examined in patients diagnosed with MS. Prior to 
our study, only a few studies had examined the role of PA and the risk of MS. Our 
results in Paper 2 are consistent with two large prospective nested case-control studies 
that found significant associations between better physical performance and lower MS 
risk among 18-19 year-old men in Norway and Sweden.76,187 However, a prospective 
study among female American nurses argued that a weak association between adult PA 
and MS risk could be due to pre-diagnostic MS-symptoms, since the trend disappeared 
when excluding the immediate 6 years of follow-up after reported PA.188 We extended 
on these previous findings by including data from several countries, both sexes, and 
adjusted for a larger set of established risk factors in the analyses.  
Since less vigorous PA may be caused by pre-diagnostic prodromal symptoms of MS 
and thus result in reverse causation, we performed a sensitivity analysis where we 
excluded participants with MS symptom onset/ index age ≤ 30 years of age. In this 
analysis, similar effect estimates compared to the whole population were found, which 
indicates that reverse causation is less likely to fully explain our findings. This is 
consistent with a prospective study on physical fitness and MS risk in young men, using 
a similar sensitivity analysis to evaluate the direction of the association.76   
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Lastly, we found no association between light PA and the risk of MS, indicating that 
not only the amounts, but also a certain intensity of PA may be of importance for the 
observed relationship. This is not unexpected, since the potential link between PA and 
MS may go via anti-inflammatory mechanisms that require exercise of moderate to 
high intensity, such as increased levels of cortisol,247 and a subsequent rise in anti-
inflammatory cytokines.193 The definition of vigorous PA in the EnvIMS-Q did not 
differentiate moderate from higher intensity levels, and therefore other studies are 
needed to examine any additional influence of high-intensity exercise on MS risk.   
5.1.3 Paper 3 
In Paper 3, we examined whether vitamin D could influence long-term disease 
progression in MS, since most studies on vitamin D and MS course have focused on 
short-term outcomes.110 One cohort study in California found no significant association 
between baseline de-seasonalized 25(OH)D levels and long-term (10 years) EDSS 
progression, but in this study, seasonal variations of 25(OH)D could not be captured 
from the infrequent annual measures during the 2-year baseline period.107 Another 
prospective study of participants originally included in the BENEFIT trial on IFN-β 
versus placebo, showed that higher 25(OH)D levels measured every six months during 
the 24-month baseline period were significantly associated with better 11-year 
cognitive performance on the PASAT test.106 In contrast to this study, we focused on 
mainly physical disability progression assessed by the EDSS score. To our knowledge, 
such a significant association between 25(OH)D levels and 10-year EDSS progression, 
has not been demonstrated before.  
Our study benefited from frequently measured 25(OH)D levels during two years, 
making the participants’ 25(OH)D levels less prone to extreme values in single 
observations, and also gave us the possibility to evaluate the influence of seasonal 
fluctuations of 25(OH)D levels on our main findings. Indeed, we showed that low 
spring levels appeared to be the main driver of the observed association, also after 
adjusting for 25(OH)D levels during other seasons. This extends on previous findings 
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of a seasonal pattern of relapse rates.89,248 Lastly, the non-linear observation of a ceiling 
effect for 25(OH)D levels above 80 nmol/L in combination with only a modest effect 
of high-dose vitamin D3 treatment in recent RCTs,108,109 and a diminished relapse rate 
when 25(OH)D levels reached 110 nmol/L in an observational study,249 suggest that 
MS patients do not need to aim for supraphysiological 25(OH)D levels.  
We found neither a clear association between indirect tobacco measures and 10-year 
disability progression, nor significant more SPMS after 10 years among classified 
tobacco users. This contrasts the findings of more rapid disease progression and earlier 
conversion to SPMS among smokers in larger cohorts. Compared to our data, the MS 
populations in these studies had longer mean disease duration at baseline (10-15 years 
versus 1.9 years),215,250 or smoking data was retrospectively collected through cross-
sectional surveys,209,216 which are more prone to misclassification errors than objective 
measures. In fact, our results are in line with two cotinine-based prospective studies by 
Munger et al.214 and Kvistad et al.218 conducted in RCT populations of the BENEFIT 
trial251 and the baseline OFAMS trial,243 respectively. In these studies, the participants 
had mainly short disease duration and early initiation of DMT, and no association 
between tobacco use and disease activity or disease progression was found during 2-5 
years. While these studies dichotomized the tobacco variable into tobacco use versus 
non-tobacco use based on pre-defined cut-off values for cotinine, we included all 
available mean levels of cotinine during the baseline period in our analyses, thus 
minimizing misclassification of a light smoker or intermittent smoker as a non-smoker. 
In the categorical analyses, the lowest quartile of cotinine had a range of 0.0- 1.2 
nmol/L, which makes smoking and other tobacco use in this group extremely unlikely. 
Still, we have to bear in mind that higher cotinine levels could represent oral snuff use, 
which has been associated with a decreased risk of MS.201,206 However, in the follow-
up study, only three participants classified as tobacco users in the baseline study 




Lastly, our findings could have been affected by an overall low disability progression 
(mean EDSS change of 0.9 points) in the population, and/or beneficial effects of 
smoking cessation,216 since 21.3% of the classified tobacco users reported no longer 
tobacco intake at follow-up. Unfortunately, our small sample size made subgroup 
analysis of continuous smokers not feasible. In summary, we were not able to detect 
any adverse effects of tobacco use in our population, which may apply to other 
populations with more active disease. 
Different measures of obesity have been associated with disease activity and/or worse 
disability (progression) in some,134,148,151 but not all154,155 studies. In our study, we 
found a non-significant trend of less disability progression among the patients with the 
highest BMI, also after adjusting for relevant covariates. In general, BMI is a 
challenging exposure since it can be a proxy for many other factors/comorbidities as 
well as a consequence of the outcome of interest (i.e. it may be prone to reverse 
causation). This means that any observed association between BMI and MS may be 
due to other (unmeasured) confounders, or a result of MS-related behavioural or dietary 
changes. Several other studies have shown that MS populations in general have lower 
BMI compared to an age-matched population.132,156-158 Although an interpretation of 
non-significant results should be made cautiously, our results may indicate that lower 
BMI reflects a more severe disease, while higher BMI reflects a more benign MS. This 
is supported by the observation of more prevalent use of potent DMT after 10 years in 







5.2 Methodological considerations and limitations  
5.2.1 Observational studies and their quality of evidence 
The three studies included in this thesis are observational of nature, which means that 
the investigator passively observes the population without making any specific 
interventions.252 In a hierarchal ranking of the level of evidence from different studies 
(Figure 9) observational studies are placed beneath the gold standard of RCT,253 in 
which randomization ensures that the groups are similar in all aspects except the 
exposure/intervention of interest; thus allowing for a causal interpretation.  
 
Figure 9. The hierarchal model of evidence. Observational studies are ranked below 
RCT and other well-designed controlled trials. Reprinted by permission from N Engl J 
Med 2000; 342:188.253 © Massachusetts Medical Society.  
 
In observational studies, one should be careful to interpret a significant association as 
causal, as these studies are more prone to various types of bias, especially confounding, 
but also different types of selection bias and measurement bias.254 A bias can be defined 
as “a systematic error in any type of epidemiologic study that results in an incorrect 
estimate of the association between exposures and outcome.”255 Any bias can threaten 
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the validity of the study; internal validity refers to how well you can rely on an observed 
association between a defined exposure and outcome within a study, while external 
validity refers to how well the findings can be generalized to other populations.256 
5.2.2 The EnvIMS study: Advantages of the study design  
MS is a relatively rare disease with a likely long latent period between a potential 
exposure of interest and disease onset. In such situations, cohort studies that 
prospectively follow a group of exposed and non-exposed individuals until the eventual 
outcome/disease occurs, require large samples, a long follow-up period, and are 
expensive to conduct.257 Therefore, a more feasible, less expensive and rapid approach 
is to design a case-control study where exposures among cases with the defined 
outcome (e.g. MS) are compared to controls from the same source population without 
the outcome. The EnvIMS study is such a case-control study, where the relevant 
exposures were retrospectively collected through the self-administered EnvIMS-Q. 
While cohort studies are often limited to the exposures included at study start and may 
lack information about relevant exposures detected at a later stage, the case-control 
design allows for a more rapid evaluation of different exposures of interest, since the 
outcome is already known.  
In the EnvIMS study, any misclassification of cases as non-cases were minimized by 
including only cases with a verified diagnosis of MS, cross-checking the controls for 
negative MS diagnosis, and including a question about MS diagnosis in the EnvIMS-
Q. To ensure a representative sample of the controls, they were frequency-matched to 
the cases by age, sex and area, as well as randomly selected from the general population 
which also produced the cases.229 Further, the EnvIMS study benefited from a large 
sample size which increased the precision in the statistical analyses, and by this reduced 
the risk of a type II error (i.e. to falsely accept a null hypothesis of no association due 
to wide confidence intervals in the estimates).258 In addition, by including several 
populations, the EnvIMS study could evaluate the consistency of findings across 
different geographical areas using the same methodology.  
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5.2.3 The EnvIMS study: Selection bias  
To induce a selection bias in an epidemiological study, the selection of participants has 
to be related to both the exposure and the outcome as a common effect.254 In case-
control studies, a selection bias can typically occur if the exposure distribution in the 
control group systematically differs from the exposure distribution in the source 
population where the cases were drawn from.255 The EnvIMS study was designed to 
minimize selection bias by using a population-based approach. However, no matter 
how optimal a selection procedure is by design, the subsequent response rates may 
induce selection bias. In the EnvIMS study, the response rates among controls were (as 
expected) lower than cases, with the lowest response rates in the Italian EnvIMS data 
(42% among cases and 21% among controls). This can be a problem, if the selection 
of participants into the study is related to both exposure and outcome. While 
responding cases are likely motivated to take part in a study due to the disease itself 
(and not the exposures of interest), the controls who participate in such studies often 
have a higher socioeconomic status,259 and may therefore have characteristics related 
to the exposures of interests that differ from the source population.  
A previous study based on the Norwegian EnvIMS data reported that the controls had 
a higher level of education compared to the cases, which may be a result of selection 
bias.260 Since higher education is associated with better health,261 the EnvIMS controls 
may have been more physically active and had lower BMI during their childhood than 
the source population. Still, our findings of a likely influence of obesity and vigorous 
PA on MS risk are in line with prospective studies of large cohorts, which are less 
prone to selection bias by the study design, since selection into the study is not affected 
by the future outcome.255 Further, another study in a complete cohort of Norwegian 
workers linked to the Norwegian MS registry observed an inverse association between 
level of education and MS risk,262 again arguing against a systematical difference 
between the  EnvIMS controls and the source population with respect to education and 
related lifestyle behaviours.  
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5.2.4 The EnvIMS study: Measurement errors and misclassification  
Measurement errors of the exposure and/or the outcome are virtually always present 
to a greater or lesser extent in any study, and may introduce measurement bias if it 
affects the association between an exposure and outcome.254 A measurement error or 
misclassification of an exposure is nondifferential if it is unrelated to the outcome; 
otherwise it is said to be differential; i.e. when measurement error of an exposure is 
affected by the disease status.254,255 Both the magnitude and the direction of any type 
of measurement bias are difficult to predict in most studies when the true value is not 
known.254  
In the EnvIMS study, non-differential misclassification of some non-diagnosed 
prodromal MS cases as controls could exist, but since MS is a rare disease, such 
misclassification is likely of minimal importance. Misclassification of controls as MS 
cases is even more unlikely, since the cases were recruited from reliable sources 
(registries and databases) dependent on a verified MS diagnosis.  
Retrospective case-control studies are prone to recall bias, a type of differential 
misclassification of exposure that occurs when the participants’ recall of a past 
exposure is affected by their disease status.254 For instance, MS cases will likely seek 
for etiological causes to their disease, and may therefore recall and report past 
exposures differently than the controls. The likelihood of recall bias is larger when the 
cases are already familiar with a known risk factor for the disease. Since body size and 
physical inactivity were not among the established risk factors for MS at the time of 
study enrollment, it is less likely that the retrospective reporting of these factors could 
have led to recall bias. Another possible recall bias could arise if the cases and the 
controls differed systematically in the way they perceived their body size. However, 
the correlation between calculated BMI and reported body size at the time of the study 
was strong and not significantly different between the groups, which argues against a 
recall bias related to this phenomenon. Rather, the results could have been influenced 
by non-differential misclassification errors, i.e that the controls and cases misclassified 
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their past body sizes and PA in a similar way (not affected by their outcome status), 
since it is challenging to remember details about exposures that took place many years 
ago. To reduce such non-differential errors, the EnvIMS-Q tried to facilitate recall by 
adapting the ages for exposures to the countries’ school system, and by encouraging 
the participants to ask close relatives/parents if their own memory on a topic was 
limited. In Paper 1 and 2 of this thesis, we did not compare the results between those 
who asked a close relative, and those who did not, which could have detected some 
meaningful differences.   
5.2.5 The EnvIMS study: Confounding and reverse causation  
In observational studies, the probability of being exposed versus not being exposed is 
likely affected by common causes of the exposure and outcome; also known as 
confounding.254 Causal interpretation of an observed association can only be made if 
there were no counfounders, or if the association has been adequately adjusted for a 
sufficient set of confounding variables, which in real life may be impossible.254 In our 
three Papers, we have used traditional statistical regression models to adjust for 
measured confounders to reduce the risk of confounding bias by observed variables, 
but there may always be unmeasured confounding, or imperfectly measured variables 
that may affect the results from these analyses. In any circumstances, it is important to 
avoid adjustments for variables that can be a common effect (and not cause) of the 
exposure and outcome, as adjusting for such a variable may induce “collider bias” in 
the estimates and lead to wrong conclusions.254  
In Paper 1 (on body size) we adjusted for the potential confounders sex, age, smoking 
habits and summer outdoor activity. Since the outdoor variable does not equal the exact 
amount of sun exposure, there is likely some residual confounding related to this 
variable. Further, we could have adjusted for level of education and amount of PA 
during adolescence, but we decided to omit them, since these factors are considered 
less specific and may include factors we had already adjusted for. In retrospect, it could 
be relevant to adjust for PA, since PA has later been associated with MS risk76,263 and 
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may also act as a mediator264 on the pathway between body size and the risk of MS, as 
explained in this figure:  
 
Figure 10. A directed acyclic graph showing the direct effect from exposure E to 
disease D (direct arrow from E to D), and the indirect effect via mediator M (arrow 
from E to M and arrow from M to D). 
 
For example, a large body size can lead to lack of energy and less PA, which in turn 
can affect the risk of MS.260,263 Adjusting for potential mediators can help us to detect 
important pathways between body size and MS risk,264 which could be of value in the 
interpretation of the findings. However, it is unlikely that adolescent PA is a major 
mediator or confounder for the association between body size and MS risk in our study, 
since adjusting for body size in the multivariable model in Paper 2 did not influence 
the estimates between PA and MS risk in any meaningful way. We therefore believe 
that we have adequately adjusted for the most relevant confounders among the 
observed variables in Paper 1.  
In Paper 2 on PA and MS risk, we adjusted for established risk factors for MS (IM, sun 
exposure via summer outdoor activity, smoking, and body size), since all these factors 
could likely affect both levels of PA and the risk of MS. The EnvIMS-Q also obtained 
information about autoimmune diseases (and their ages of onset) which could possibly 
influence the adolescent level of physical activity and the risk of MS, but it is more 
common to be diagnosed with MS without any co-existing autoimmune disorder,265 or 
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they tend to develop after MS onset.266 In both Paper 1 and Paper 2, we should also be 
aware of unmeasured and residual confounding that we could not account for.   
The possibility of reverse causation- a form of confounding254- needs to be addressed 
when interpreting the association between physical activity and MS, since prodromal 
symptoms before MS onset may affect PA and the risk of definitive MS. We tried to 
evaluate this by excluding participants with symptom onset ≤ age 30 years in a 
sensitivity analysis, ensuring an interval of at least 10 years between reported PA and 
MS symptoms. Later published studies investigating clinical,267,268 cognitive,269 and 
biochemical data270 on prodromal MS have confirmed that this interval is a reasonable 
choice. Reassuringly, no apparent reverse causation was found in our study, nor in a 
similar sensitivity analysis conducted in a large prospective male cohort exploring the 
association between physical performance and the risk of MS.76  
5.2.6 The OFAMS studies: Sample size and selection bias 
The OFAMS population was originally recruited for an RCT on omega-3 fatty acids, 
and the sample size was based on the power calculations and effect assumptions made 
in advance for this purpose. However, for later observational studies in the same cohort, 
the characteristics and small size of the population could challenge the interpretations 
of the findings for several reasons: First, the OFAMS population may be less 
representative of a general MS population, since the specific inclusion and exclusion 
criteria in the study243 excluded patients with severe comorbidities, and/or patients with 
active disease who could not delay the initiation of DMT. Indeed, we found that the 
OFAMS population had a low mean EDSS progression over 10 years (mean 
progression of 0.9 points), and 23.3% among those with an inflammatory RRMS 
phenotype (N=73) did not use any DMT at the follow-up visit. Second, small sample 
sizes are prone to type II error (i.e. falsely accepting a null hypothesis),258 as a small 
sample generally leads to increased random variation and decreased precision. In 
addition, cohort studies of any size can suffer from a selection bias known as attrition 
bias; a systematic difference related to the exposures and outcome between those who 
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are lost to follow-up and those remaining in the study.257 For example, if heavy smokers 
with a more severe disease were less likely to participate in the follow-up study, this 
could have led to an attrition bias in the estimates. Fortunately, EDSS scores at follow-
up were obtained from 90.9% of the eligible participants from the baseline study, 
making attrition bias less likely.  
5.2.7 The OFAMS studies: Reverse causation  
Lifestyle factors are somewhat challenging to examine in the context of a disease, since 
the disease itself may modify the factors and lead to reverse causation. For vitamin D, 
most prospective studies and larger trials with the exposure measured before the 
outcome, have shown that vitamin D supplements and/or higher 25(OH)D levels likely 
reduce inflammatory activity and may delay progression.110 On the other hand, there is 
some research arguing that low vitamin D can be a consequence of inflammation or 
poor health in patients with MS, based on minor to no effect in small randomized trials 
on vitamin D supplementation in MS .111 In our study, the vitamin D levels preceded 
the follow-up EDSS score by a long period, and it is therefore unlikely that reverse 
causation could explain the findings in our study. Although we adjusted for possible 
disease-related confounders during the baseline period, this cannot tell us the direction 
of the remaining association between vitamin D and long-term disease progression. 
Still, our results could have been attenuated by a large number of participants taking 
vitamin D containing supplements in the follow-up period, possibly motivated by 
disease severity in some patients. 
The lack of an association between tobacco use and disease progression in our study 
could be explained by reverse causation in a setting where more severe disease at 
baseline affected the tobacco use/smoking at follow-up. Indeed, the OFAMS data show 
(i) higher EDSS score (corresponding to more severe disease) in the highest compared 
to the lowest quartile of cotinine levels in the baseline study (mean EDSS at the last 
visit 2.5 versus 1.8, respectively), and (ii) as many as 50% (11/22) of the patients in the 
highest quartile reported no longer tobacco use at the follow-up visit. Therefore, our 
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results could reflect the “effect” of disease severity on smoking cessation, which in turn 
may reduce disease progression in MS.216 Finally, reverse causation may also play a 
role in the observed non-significant trend between higher BMI and less EDSS 
progression, as previously discussed. For example, dietary and nutritional changes due 
to more severe MS disease or co-existing depression may lead to weight loss, resulting 
in an inverse relationship between BMI and MS disability.  
5.2.8 The OFAMS studies: Confounding and other limitations  
In Paper 3, we adjusted for a number of potential confounders related to lifestyle and 
disease status available in the OFAMS baseline study. Most of them were objectively 
measured, which reduces the possibility of under-reporting and measurement errors. 
At the follow-up visit, the patients received a questionnaire on lifestyle which inquired 
about past and current vitamin D-related dietary habits, use of vitamins and other 
supplements, amounts of summer outdoor activity (a proxy for sun exposure), smoking 
and snuff habits, and frequency of vigorous PA during the last 10 years. Although it 
could be tempting to include some of these retrospective measures as covariates in our 
regression analyses, they are less precise and could also introduce recall bias into the 
analyses. We therefore decided to keep most of this additional information outside our 
statistical analyses. Instead, we used these self-reported data to explain some of the 
findings in our study. In addition, there may still be some unmeasured and residual 
confounding affecting our estimates.  
As already discussed, cotinine is an imperfect marker of tobacco smoking, since it 
reflects nicotine intake of any source. However, this is likely of less importance in our 
study, since only three participants classified as tobacco users in the baseline study 218 
reported a history of solely snuff use in the follow-up study. Although we categorized 
cotinine levels differently in our analyses, the self-reported data obtained at follow-up 
confirm no history of smoking or snuff use in the first quartile of cotinine (makes it 
valid as a reference group). Further, all the cotinine levels in the highest quartile 
represent classified tobacco users, with only one cotinine value from a participant with 
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a tobacco history of solely snuff use. Surprisingly, for two other values in the highest 
quartile, the participants reported neither previous smoke, nor oral snuff at follow-up. 
Whether this represents measurement errors or cotinine levels related to other nicotine 
sources is unknown.  
Finally, the EDSS score as an objective measure of disability has some limitations as 
well, due to its inter-rater variability, the dominant focus on ambulatory dysfunction 
for EDSS scores of 4 and above, and that it is a better tool for physical than cognitive 
disability.271 However, since the EDSS score is validated, widely used and accepted, 
and since most OFAMS participants did not progress to scores above 4, it is still a 
valuable measure that allows for comparisons with many other studies using the same 






6. Conclusions and future perspectives   
In this thesis, we found that overweight and obesity in adolescence and young 
adulthood is associated with an increased risk of MS in Norway, and we further 
observed that larger amounts of regular vigorous PA in different geographical areas 
may reduce the risk of MS. Although our studies based on the EnvIMS data have some 
limitations due to the retrospective study design, the results are consistent with findings 
from large prospective cohorts. In our third study, we observed that higher 25(OH)D 
levels may reduce long-term disability progression, and that seasonal fluctuations with 
25(OH)D levels below 80 nmol/L during winter and early spring at higher latitudes 
seem to drive this association. Based on our research and the results from other studies 
on vitamin D in MS, we recommend that MS patients should aim for 25(OH)D levels 
above 80 nmol/L throughout the year and use supplements when needed. For tobacco 
use and BMI, no clear associations with disability progression were found in our data, 
although they may still be of relevance in other populations. 
Since young adulthood is a period that has been less explored in the studies on obesity 
and MS, more studies are needed to confirm that excess body weight in young 
adulthood may also be of importance for MS risk. Further, we need some more 
knowledge about the specific (biological) factors related to BMI/body size that are of 
greatest importance in the pathogenesis of MS. A randomized controlled study on 
calorie restriction among obese teenagers is unfortunately not feasible since MS is a 
rare disease with a likely long latent period. In Italy, preferably prospective studies on 
obesity and the risk of MS should be performed to assess whether the negative findings 
in the EnvIMS data represents a true lack of association in this country. The published 
studies on PA and the risk of MS have shown somewhat conflicting results, and large 
prospective studies with more detailed and accurate information on amounts and 
intensity of PA in adolescence and adult years should be conducted to determine the 
role of different levels of PA on MS risk.  
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For vitamin D, large cohort studies with a representative population-based sample and 
global assessment of disability progression with clinical, cognitive and MRI measures 
(i.e. atrophy rate) should be performed to further explore whether vitamin D has a true 
impact on long-term prognosis in MS. Since the evidence on BMI and disease course 
is conflicting and may be prone to reverse causation, a randomized study with a specific 
dietary intervention in overweight MS patients could better clarify whether body 
composition has adverse effects on MS inflammation and disease course. For smoking 
and tobacco intake, a combination of objective cotinine measures along with detailed 
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A B S T R A C T   
Background: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse 
disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains 
unclear. Therefore, we explored whether these modifiable lifestyle factors were associated with 10-year clinical 
disability progression in patients with MS. 
Methods: In this prospective study, a cohort of 88 patients with relapsing-remitting MS completed a randomized 
controlled study on ω-3 fatty acids between 2004 and 2008. During 24 months, serum 25-hydroxyvitamin D (25 
(OH)D), serum cotinine (nicotine metabolite), and BMI were repeatedly measured. In 2017, a follow-up study 
was conducted among 80 of the participants, including disability assessment by the Expanded Disability Status 
Scale (EDSS). Linear regression was used to explore associations between the lifestyle factors and the EDSS 
change over 10 years. 
Results: Higher seasonally adjusted 25(OH)D levels were associated with lower 10-year EDSS progression (change 
in EDSS per 1 SD increase in 25(OH)D in a model adjusted for sex, age and baseline EDSS: -0.45 point, 95% CI: 
-0.75 to -0.16, p=0.003). Further adjustments for potential confounders related to lifestyle and disease status 
gave similar results. The association was mainly driven by low 25(OH)D levels during spring, as well as 
seasonally adjusted levels below 80 nmol/L. No clear association was found for BMI and cotinine. 
Conclusion: Lower 25(OH)D levels, but apparently not tobacco use or higher BMI, were significantly associated 
with worse long-term disability progression in MS.   
Abbreviations: DMT, disease-modifying treatment; 25(OH)D, 25-hydroxyvitamin D; RCT, randomized controlled trial; IFN-β, interferon beta 1a; aHSCT, autol-
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1. Introduction 
Multiple sclerosis (MS) is a disabling chronic disease with several 
disease-modifying treatment (DMT) options, but so far, no curable 
treatment exists (Dobson and Giovannoni, 2019). Established risk factors 
related to lifestyle such as vitamin D deficiency, tobacco smoking, and 
obesity may also affect disease course (Waubant et al., 2019). Higher 
serum levels of 25-hydroxyvitamin D (25(OH)D) have been associated 
with less radiological inflammatory activity and lower relapse rate in 
observational studies (Smolders et al., 2019). However, two larger ran-
domized controlled trials (RCTs) on high dose vitamin D supplementation 
failed to demonstrate a clear effect on relapse rate and disability pro-
gression in the intention-to-treat population (Hupperts et al., 2019, Camu 
et al., 2019). Further, several (Hernan et al., 2005, Healy et al., 2009, 
Manouchehrinia et al., 2013), but not all (Koch et al., 2007, Kvistad et al., 
2016, Munger et al., 2015) studies, suggest that smoking increases the risk 
of a faster disease progression and earlier transition to secondary pro-
gressive MS (SPMS). For obesity, some studies indicate that higher body 
mass index (BMI) leads to more disease activity through weaker therapy 
response (Kvistad et al., 2015, Huppke et al., 2019), and may affect brain 
volume loss (Mowry et al., 2018), whereas other studies have failed to 
demonstrate any association between BMI and disease progression 
(Pilutti et al., 2012, Bove et al., 2016). 
Only a few studies have examined associations between lifestyle 
factors and long-term disability progression in MS (Cortese et al., 2020, 
University of California, San Francisco MS-EPIC Team, 2016). To 
address this, we conducted a study to examine whether 25(OH)D levels, 
tobacco use, and BMI were associated with disability progression over 
10 years, using prospective data from a well-defined Norwegian cohort 
of patients with MS. 
2. Methods 
2.1. Study population and design 
2.1.1. The OFAMS baseline study 
A total of 92 patients with relapsing-remitting MS (RRMS) aged 18- 
55 years were enrolled in an RCT on marine ω-3 fatty acids versus pla-
cebo (the OFAMS study) between 2004 and 2006, and then closely 
followed for 24 months. A detailed description of the study is reported 
elsewhere (Torkildsen et al., 2012). In the following text, we will refer to 
this study as “the baseline study”. Frequent clinical examinations, blood 
samples and MRI scans of the brain were performed during the study 
period. No particular advice on lifestyle changes or vitamin D supple-
mentation was given to the patients. Overall, the study demonstrated no 
significant effect of ω-3 fatty acids on disease activity (Torkildsen et al., 
2012). However, in subsequent analyses, lower 25(OH)D levels were 
associated with more inflammatory MRI-activity before initiation of 
subcutaneous interferon beta 1a (IFN-β) at study month 6 (Loke-
n-Amsrud et al., 2012), and higher BMI was associated with more dis-
ease activity after initiation of IFN-β (Kvistad et al., 2015). 
2.1.2. The OFAMS follow up study 
In 2017, the OFAMS population was invited to a 10-year follow-up 
study to evaluate disease progression and current disability status. A 
trained neurologist at each participating centre performed a clinical 
examination of the patients. In addition, the patients answered a ques-
tionnaire regarding lifestyle habits, including sun exposure and tobacco 
use (smoking and/or snuff use) during the last 10 years. 
2.2. Ethical approvals and Patient Consents 
The OFAMS baseline study and the OFAMS follow-up study were 
approved by the Regional Committee for Medical and Health Research 
Ethics in Western Norway. All participants gave their written informed 
consent prior to the studies. 
2.3. Assessment of lifestyle factors in OFAMS baseline study 
2.3.1. Vitamin D measurement 
Serum samples were collected at the baseline visit, and then at month 
1, 3, 6, 7, 9, 12, 18, and 24. The samples were stored at -80◦C until 
simultaneous analysis of all nine samples from each patient at the 
Department of Medical Biochemistry, St. Olav’s University hospital, 
Trondheim, Norway (Loken-Amsrud et al., 2012). 25(OH)D levels in 
nmol/L were measured by radioimmunoassay (RIA kit; ImmunoDiag-
nostic Systems, Boldon, UK). The coefficient of variation was 5.4% at 29 
nmol/l and 6.3% at 112 nmol/l. 
2.3.2. Cotinine measurement 
Cotinine levels, a sensitive and specific biomarker for nicotine intake 
(SRNT Subcommittee on Biochemical Verification, 2002), were 
measured simultaneously in serum samples collected at baseline visit, 
month 6, 12, 18, and 24 (Kvistad et al., 2016). The analysis was per-
formed by liquid chromatography-tandem mass spectrometry (Bevital 
AS, Bergen, Norway). The within-day coefficient of variation was 2.0% 
to 6.6%, and the between-day coefficient of variation was 3.9%. The 
cut-off value for recent tobacco use was set to cotinine levels > 85 
nmol/L, with tobacco users defined as having > 85 nmol/L in ≥ 60% of 
the samples. 
2.3.3. Body mass index 
The participants’ height (in meters) and weight (in kg) were 
measured at screening, and then at baseline visit, month 1, 3, 6, 7, 9, 12, 
18, and 24. From these values, BMI at each visit was calculated as kg/ 
m2. 
2.4. Other relevant covariates 
Current use of DMT at follow-up was categorized as “none”, “less 
potent” (IFN-β, glatiramer acetate, teriflunomide, and dimethyl fuma-
rate) and “potent” (fingolimod, natalizumab, autologous hematopoietic 
stem cell transplantation (aHSCT), and rituximab). For disease activity, 
we included two variables from the baseline study: the cumulative 
number of combined unique activity (CUA) lesions (Torkildsen et al., 
2012) on subsequent MRI brain scans, and the annual relapse rate. 
At the follow-up visit, the participants were asked about the fre-
quency of outdoor activity in summer season (April-September) 10 years 
ago, 5 years ago and last year, categorizing this into “< 1 time per 
week”, “1-2 times per week”, “3-4 times per week” and “approximately 
daily”. From these data, we created a cumulative sun exposure variable. 
2.5. Outcome measure 
2.5.1. EDSS progression 
The disability status was assessed by the Expanded Disability Status 
Scale (EDSS) (Kurtzke, 1983) at baseline visit, month 6, 12, 18, and 24 
during the baseline study and repeated once in the follow-up study 10 
years later. The EDSS progression was defined as the EDSS change from 
the last score in the baseline study until the score at follow-up. For all 
patients but two the last EDSS score was at month 24; one patient had 
the last score at month 12 and the other one at month 18. 
2.6. Missing values 
92 patients were screened to participate in the baseline study, but 
four were lost to follow-up during the first six months of the study. In the 
follow-up study, 85 of the 91 patients still alive (93.4%) gave their 
consent to participate, including 81 of the 88 patients who completed at 
least 12 months of the baseline study. However, EDSS score at follow-up 
was missing for one of these 81 patients, leaving 80 patients eligible for 
the main analyses. 
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2.7. Statistical analyses 
For each lifestyle factor, we estimated the mean value per patient 
based on all available measurements during the baseline study. Since 
vitamin D levels vary with season in Norway, the 25(OH)D levels were 
seasonally adjusted by a sine function modelled within the baseline 
study, as previously described (Saltyte Benth et al., 2012). 
We used linear regression models to estimate the association be-
tween the lifestyle factors and the EDSS progression from the last score 
in the OFAMS baseline study to the assessment in the follow-up study. 
All exposures were modelled as both categorical (quartiles) and 
continuous variables to maximize power and to explore possible 
nonlinear associations. In continuous analyses, we standardized the 
variables (mean = 0, standard deviation (SD) = 1) to estimate the 
change in EDSS per 1 SD increase in the exposure variable. To test for a 
linear trend across the quartiles, the median value of each quartile was 
included in the regression model as a continuous variable. All available 
measurements in the OFAMS baseline study were used to standardize 
and categorize variables. All models were adjusted for sex, age and 
baseline EDSS score (= last score in the baseline study). In multivariable 
models, we mutually adjusted for all three lifestyle factors, disease ac-
tivity (CUA and annual relapse rate) in the baseline study, disease 
duration (from year of diagnosis until follow-up), and use of DMT at 
follow-up. We also adjusted for cumulative sun exposure in the follow- 
up period, but as this only had a minor influence on the effect esti-
mates, we omitted this variable in the final models. 
To illustrate the monthly fluctuations of 25(OH)D levels in our pop-
ulation, a Locally Estimated Scatterplot Smoothing (LOESS) curve was 
fitted to the available measures, with corresponding 95% confidence in-
tervals (CI). To evaluate whether an association between 25(OH)D levels 
and EDSS progression varied by season, we computed a dichotomized 
variable of < median and ≥ median 25(OH)D levels per season based on 
each patient’s mean 25(OH)D level for that season. The four seasons were 
summer (June-August), fall (September-November), winter (December- 
February), and spring (March-May). We then included the dichotomized 
seasonal variables (< median or ≥ median) as independent variables in 
linear regression analyses, with the change in EDSS score as the depen-
dent variable, adjusted for sex, age and baseline EDSS score. Finally, to 
investigate whether there was a nonlinear relationship between season-
ally adjusted 25(OH)D levels and disease progression, we plotted a 
LOESS-curve to the available data. 
All the statistical analyses were performed in IBM SPSS Statistics, 
version 25.0 (SPSS Inc., Chicago, Ill., USA). The plots were made in R 
version 3.6.0 (The R Foundation) using the ggplot2 package. P-values 
were considered significant at values <0.05. All tests were two-sided. 
3. Results 
3.1. Patient characteristics 
The study population comprised 80 participants who completed 
more than 12 months in the baseline study and had an available EDSS 
score in the follow-up study. Table 1 gives the main baseline charac-
teristics of this population. The mean EDSS score increased from 1.9 (SD: 
0.84) at the baseline visit to 2.8 (SD: 1.6) at the follow-up visit, and 
seven (8.8%) of the patients converted to SPMS during the follow-up 
period. At follow-up, 72.5% received any kind of DMT, including 
seven patients still on IFN-β and two patients on past aHSCT treatment. 
Fewer used tobacco (40.0% vs. 61.3% in the baseline study), and 76.3% 
used vitamin D containing supplements in various doses and formulas. 
For most patients, BMI remained stable over the years, with mean BMI 
25.6 kg/m2 (SD: 4.2) and 25.7 kg/m2 (SD: 4.6) during the baseline and 
follow-up study, respectively. 
3.2. Vitamin D 
Higher 25(OH)D levels were significantly associated with lower 10- 
year EDSS progression (Table 2). In the continuous model adjusted for 
sex, age and baseline EDSS score, 1 SD increase in seasonally adjusted 
average 25(OH)D levels was associated with 0.45 point (95% CI: 0.16- 
0.75, p=0.003) lower progression in EDSS scores at follow-up. Further 
adjustment for other covariates, including mean cotinine levels, mean 
BMI values and disease activity during the baseline study, did not in-
fluence the results. In the categorical analyses, there was a significant 
dose-response relationship between 25(OH)D and change in EDSS score 
with a p-trend of 0.024 in the simplest model (Table 2). The effect es-
timates and the p-trend remained similar when more covariates were 
added to the model. 
Fig. 1 illustrates the seasonal fluctuation of repeated measures of 25 
(OH)D throughout the baseline study, with the highest levels seen in 
August and the lowest levels seen in March. In the model that included 
dichotomized 25(OH)D variables for all four seasons, only higher 
(≥ median) 25(OH)D levels during the spring, when the levels were 
lowest, were significantly associated with 10-year EDSS progression 
(Fig. 2). 
When exploring the possible nonlinear relationship between 25(OH)D 
and disease progression with a LOESS-curve (Fig. 3), an increase in 
seasonally adjusted 25(OH)D levels from around 50-60 nmol/L to 80 nmol/ 
L was associated with approximately one point decrease in EDSS progres-
sion, whereas little additional benefit was seen for higher 25(OH)D levels. 
3.3. Cotinine levels 
Tobacco use based on cotinine levels showed no significant associ-
ation with EDSS progression, neither in the simple model adjusted for 
sex, age, and baseline EDSS score, nor in the models adjusted for addi-
tional variables (Table 2). Although five of seven patients (71%) who 
converted to SPMS were classified as tobacco users during the baseline 
study, this finding was not significant (p= 0.70) according to Fisher’s 
exact two-sided test for small samples. 
3.4. BMI 
For BMI, there was a tendency towards a beneficial effect for the 
patients with BMI values in the highest quartile, but no significant dose- 
response curve was present (Table 2). We found a similar non-significant 
trend in the continuous model. 
4. Discussion 
In this prospective study, we found a significant and consistent as-
sociation between higher 25(OH)D levels and lower 10-year disability 
progression independent of potential confounders related to lifestyle 
Table 1 
Characteristics of the study population at OFAMS baseline visit or during the 
baseline study.  
Variable Values 
Patients, N 80 
Females, N (%) 52 (65) 
Age, mean (SD) 38.3 (8.3) 
Years from diagnosis, mean (SD) 1.9 (3.2) 
EDSS score, mean (SD) 1.9 (0.84) 
Seasonally adjusted 25(OH)D during baseline study, mean (SD) 74.1 (18.1) 
Tobacco users during baseline study, N(%)a 49 (61.3) 
BMI in kg/m2 during baseline study, mean (SD) 25.6 (4.2) 
SD: standard deviation; 25(OH)D: 25-hydroxyvitamin D nmol/L; BMI: body 
mass index. 
a Tobacco users defined as serum cotinine levels > 85 nmol/L in ≥60% of five 
consecutive samples. 
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and disease status. The association was mainly driven by levels during 
spring when 25(OH)D reached its seasonal nadir. Further, a ceiling ef-
fect in the association appeared around 80 nmol/L, as there were only 
minor changes in disease progression for 25(OH)D increases above this 
level. Tobacco use and BMI were not significantly associated with long- 
term disability in our study. 
Our findings on vitamin D are consistent with previous findings on a 
likely role of vitamin D on disease course in MS. While several studies 
have shown a significant relationship between vitamin D levels and 
inflammatory activity in MS over a few years, few have demonstrated 
any significant association between vitamin D levels and disease 
progression (Smolders et al., 2019). This may be due to shorter 
follow-up time, as use of DMTs delay disability progression and the time 
to secondary progressive MS (Claflin et al., 2018, Brown et al., 2019). A 
recent study found poorer long-term (11 years) cognitive performance in 
the Paced Auditory Serial Addition Test in patients with lower 25(OH)D 
levels at baseline (Cortese et al., 2020), which in part supports our re-
sults. Thus, a longer observational period may be necessary to detect a 
potential effect of vitamin D levels on physical and cognitive disability 
scores. 
In our data, a ceiling effect appeared in the association between 25 
(OH)D and disability progression as there was almost no additional 
Table 2 
The association between mean values of lifestyle factors during the baseline study and the 10-year EDSS progression from last EDSS score in the baseline study.   
Quartile 1 Quartile 2 Quartile 3 Quartile 4  Per 1 SD increasea  
Lifestyle factors  Change in EDSS(95%CI) Change in EDSS(95%CI) Change in EDSS(95%CI) p- 
trend 
Change in EDSS (95%CI) p- 
value 
25(OH)Db        
Patients, N 20 18 21 21    
Median (range), nmol/L 54.9 (36.4- 60.1) 66.9 (60.3- 70.7) 77.5 (71.1- 83.8) 97.6 (84.0- 118.4)    
Model 1c Reference 0.13 (-0.67- 0.93) -0.61 (-1.41- 0.19) -0.78 (-1.59- 0.03) 0.024 -0.45 (-0.75- -0.16) 0.003 
Model 2d Reference 0.29 (-0.53- 1.11) -0.59 (-1.38- 0.21) -0.76 (-1.56- 0.05) 0.022 -0.46 (-0.75- -0.17) 0.002 
Model 3e Reference -0.06 (-0.93- 0.82) -0.86 (-1.72- 0.00) -0.99 (-1.83- -0.15) 0.010 -0.49 (-0.79- -0.20) 0.002 
Cotinineb        
Patients, N 20 19 19 22    
Median (range), nmol/L 0.4 (0.0- 1.2) 123.8 (1.2- 400.8) 738.9 (407.7- 946.6) 1140.6 (980.3- 2443.6)    
Model 1c Reference 0.55 (-0.25- 1.35) 0.30 (-0.51- 1.10) -0.17 (-0.98- 0.64) 0.353 -0.09 (-0.38- 0.20) 0.557 
Model 2d Reference 0.48 (-0.28- 1.24) 0.16 (-0.62- 0.94) -0.11 (-0.88- 0.66) 0.393 -0.07 (-0.34- 0.20) 0.618 
Model 3e Reference 0.34 (-0.45- 1.12) -0.07 (-0.88- 0.75) -0.19 (-0.98- 0.60) 0.296 -0.09 (-0.37- 0.20) 0.538 
BMIb        
Patients, N 22 20 19 19    
Median (range), kg/m2 21.5 (17.7- 22.9) 23.8 (22.9- 25.2) 26.3 (25.3- 28.2) 31.1 (28.8- 38.3)    
Model 1c Reference 0.04 (-0.75- 0.82) -0.10 (-0.90- 0.69) -0.51 (-1.31- 0.28) 0.157 -0.20 (-0.48- 0.08) 0.160 
Model 2d Reference 0.11 (-0.64- 0.86) -0.13 (-0.89- 0.63) -0.43 (-1.19- 0.33) 0.182 -0.20 (-0.47- 0.06) 0.134 
Model 3e Reference 0.02 (-0.74- 0.78) -0.15 (-0.91- 0.62) -0.40 (-1.16- 0.36) 0.247 -0.18 (-0.44- 0.09) 0.189 
SD: standard deviation; CI: confidence interval; 25(OH)D: 25- hydroxyvitamin D; BMI: body mass index. 
a 1 SD for seasonally adjusted 25(OH)D =18.7 nmol/L, 1 SD for mean cotinine= 523.8 nmol/L, 1 SD for mean BMI= 4.2 kg/m2 
b Mean values for the baseline period based on N consecutive samples, where N= 9 for seasonally adjusted 25(OH)D, N=5 for cotinine and N=10 for BMI. 
c Model 1: Adjusted for sex, age and EDSS score at last visit in the baseline study. 
d Model 2: Model 1 + mutually adjusted for 25(OH)D, cotinine and BMI as standardized continuous variables. 
e Model 3: Model 2 + further adjusted for disease duration from year of diagnosis until follow-up (2017), use of disease-modifying treatment at follow-up (none, less 
potent, potent), brain MRI activity (cumulative Combined Unique Activity) and relapse rate during the baseline study. 
Fig. 1. The seasonal fluctuation of 25-hydroxyvitamin D levels based on sample analyses in the baseline study shown by a fitted LOESS curve with 95% confi-
dence intervals. 
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benefit for levels above 80 nmol/L. This finding is in line with a previous 
observational study among 156 RRMS patients on IFN-β or glatiramer 
acetate who were supplemented with vitamin D3. During follow-up, the 
relapse incidence rate significantly decreased until 25(OH)D levels 
reached 110-120 nmol/L - above this, the relapse rate stabilized 
(Pierrot-Deseilligny et al., 2012). Overall, this may suggest that the 
optimal 25(OH)D level for MS patients could lay within a high normal 
range of 80-120 nmol/L. 
In our study population, 25(OH)D levels during spring had the 
strongest association with long-term disability. This may be explained 
by the “vitamin D winter” (Engelsen et al., 2005) period at latitudes 
above 50◦ when UVB radiation, the main natural source of vitamin D 
(Prietl et al., 2013), is too weak to induce any meaningful cutaneous 
synthesis of pre-vitamin D (Engelsen et al., 2005). This lack of synthesis 
cannot be fully compensated by a 15-25 days half-life of 25(OH)D in 
non-supplemented individuals (Martinaityte et al., 2017), making early 
spring extra prone for insufficient levels. Other studies have similarly 
found higher relapse rate during (early) spring (Miclea et al., 2017, 
Spelman et al., 2014). Vitamin D supplementation can compensate for 
the seasonal UVB-related variations in 25(OH)D (Miclea et al., 2017), 
and may also increase the half-life through storage in adipose tissue 
(Martinaityte et al., 2017), thus likely avoiding the lowest levels during 
the winter months at high latitudes. 
The association between vitamin D and MS can be explained through 
plausible biological mechanisms. Both antigen-presenting cells of the 
innate immune system and T- and B-lymphocytes of the adaptive im-
mune system express vitamin D receptors and are able to synthesize the 
active vitamin D compound calcitriol (Prietl et al., 2013, Hart et al., 
2011). Through various mechanisms, calcitriol modulates the immune 
system into a more tolerogenic and anti-inflammatory state, thus likely 
Fig. 2. The association between dichotomized 
seasonal 25-hydroxyvitamin D levels and long- 
term EDSS progression. 
The seasonal 25-hydroxyvitamin D levels are 
dichotomized into “< median” and “≥ median” 
values and further adjusted for sex, age and 
EDSS score at last visit in the baseline study. 
Change in EDSS is the difference between the 
EDSS score at follow-up and the last EDSS score 
in the baseline study. The plots on the right side 
illustrate the estimates. 25(OH)D: 25-hydroxy-
vitamin D; IQR: interquartile range; CI: confi-
dence interval.   
Fig. 3. Seasonally adjusted 25-hydroxyvitamin D levels and the increase in EDSS score fitted by a LOESS curve. 
The increase in EDSS score is defined as the follow-up EDSS score subtracted by the last EDSS score in the baseline study. 
The vertical lines correspond to the fifth, 25th, 50th, 75th, and 95th percentile of serum 25-hydroxyvitamin D levels. 
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preventing and down-scaling autoimmune actions (Prietl et al., 2013). 
On the other hand, UVB radiation itself has likely immunomodulatory 
effects independent of the vitamin D pathway (Hart et al., 2011). 
However, when adjusting for cumulative sun exposure in our models, 
only a minor influence on the estimates was seen, suggesting that our 
results likely represent effects of vitamin D rather than UVB radiation. 
In contrast to other cohorts (Healy et al., 2009, Manouchehrinia 
et al., 2013), we found no significant association between tobacco use 
and EDSS progression. Our results may have been affected by generally 
low disease progression in the population and beneficial effect of 
smoking cessation (Ramanujam et al., 2015) during follow-up (21.3% 
fewer tobacco users at follow-up visit). Since we used a nicotine 
metabolite to classify tobacco use in the baseline study, the results could 
potentially have been influenced by snuff use, which also contains 
nicotine and has been associated with a decreased risk for MS (Hed-
strom et al., 2009). However, only three tobacco users in the baseline 
study reported a history of solely snuff use at follow-up, making it un-
likely that our results can be explained by many snuff-users relative to 
smokers. 
For BMI, we observed a non-significant trend towards less EDSS 
progression with higher BMI. Studies on BMI and long-term outcomes in 
MS may be difficult to interpret, as MS itself or changes in diet and ac-
tivity may affect BMI (Habek et al., 2010), making findings prone to 
reverse causation. Patients with MS tend to have lower mean BMI 
(Nortvedt et al., 2005, Dardiotis et al., 2019), and gain less weight with 
age as compared to the general population (Bove et al., 2016, Wesnes 
et al., 2015), which could suggest that maintaining a higher BMI over 
the years reflects a more benign MS with less chronic disease burden 
affecting weight. This is consistent with other observations in our study, 
as use of potent DMT at follow-up was more prevalent in the lowest BMI 
quartile (54.5%) than in the highest quartile (31.6%). 
Our study has several strengths. First, it benefits from a prospective 
design, a well-defined cohort, and a long follow-up time. Second, the 
lifestyle variables are based on objective and repeated measures over 24 
months, making the results less prone to extreme values in single 
observations. Third, we could adjust for several potential confounders 
and explore the importance of seasonality in the relationship between 25 
(OH)D levels and disability progression. 
There are also some limitations to our study. The relatively small 
sample size may have limited the statistical power to detect associations 
in our study (i.e., increasing the likelihood of a type II error). In addition, 
the low level of disease progression in the study group could have 
influenced our findings, and factors that were not associated with pro-
gression in our study (e.g., smoking and BMI) may be more relevant for 
patients with a more aggressive disease course. Since the baseline study 
and the follow-up study was separated by a long period, we did not have 
detailed information on lifestyle habits between the two studies. It is 
therefore possible that lifestyle changes, such as increasing use of 
vitamin D supplements, may have attenuated the associations. At follow- 
up, only one EDSS score per patient was available, which could have 
been influenced by the patients’ mood and level of fatigue at the time of 
assessment. However, such day-to-day changes may act in both di-
rections, and are therefore less likely to affect the results. Our study 
population was originally recruited for a randomized clinical trial based 
on specific inclusion and exclusion criteria (Torkildsen et al., 2012), and 
may not be fully representative of the general MS population. Still, our 
findings on vitamin D are consistent with previous prospective studies 
and are biologically plausible. Lastly, we cannot exclude the possibility 
that our findings may be affected by residual or unmeasured con-
founding that we could not account for. 
5. Conclusions 
In summary, we found a significant association between higher 
vitamin D levels and lower long-term disability progression in patients 
with MS, suggesting that vitamin D may have a favourable effect on 
long-term outcomes in MS. This association seems to be driven by sea-
sonal low levels during late winter/early spring at latitudes above 50◦. 
No clear association was found between tobacco use or BMI and long- 
term disability scores, indicating that these factors may have less rele-
vance for long-term prognosis. 
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1. Year of birth:                       Your age now: 
 
 
Are you a woman               or a man      
 
 
Please complete the following table with information 
about where you lived at the following ages: 
(Please print) 
 Town/City Province/State & 
Country 
At birth ________________ _______________ 
 






















































2. What is the highest level of education attained by you, your mother and your 
father? 
 Yourself Your mother Your father 
Some  elementary school education    
Completed elementary school    
Some high school education    
Completed high school    
CEGEP or college diploma    
Technical or trade school diploma    
University degree (Bachelor’s)    
Graduate studies     
 ►(Specify level e.g. Masters, PhD, 
etc)   _______ _______ _______ 
Don’t know    
 
 
3. What are your birth parents’ ethnic backgrounds? 
 Your father Your mother 
White   
Chinese   
Latin American   
Arab   
Aboriginal (e.g., North American Indian, Inuit)   
West Asian (e.g., Iranian, Afghan)   
Black    
Japanese   
Southeast Asian (e.g., Vietnamese, Cambodian)   
Korean   
South Asian (e.g., Indian, Sri Lankan)   
Filipino   
Other:   
                                                  (Specify)  __________ _________ 
 
4. Please indicate in the box how many brothers and sisters you have.  Include all children who lived with you 
during your childhood. If you are an only child, enter 0 in the box. 
 
     
Please indicate the years of their births and their gender. 
 
1 2 3 4 5 6 
Year of Birth: 
      
Sex (M/F) M    F  M    F  M    F  M    F  M    F  M    F  
   SECTION 1: DEMOGRAPHICS  
 
 
        
 
This Questionnaire will be read by an automatic optical reader 
• Please use a blue or black pen to indicate your answer choice.                                         Participant ID: ___________________________ 
 
• Put an X in the box  which corresponds to your correct answer choice :   
• If you put an X in the wrong box, please fill in the whole box completely  and then select the correct answer by placing  an X in 
the correct box  
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1. Please select the corresponding box below the colour that best matches the natural colour of your skin at the inner upper arm 
(without tanning). Set the colour chart against the inner part of your arm, between the elbow and the armpit, and select the number 
that corresponds best to the part of the figure that is closest to the colour of your skin. 
 
2. What is the tanning reaction of your skin to its first sun exposure in the summer, with no use of sunscreen? 
1. Always burn, never tan  
2. Usually burn, tan less than average (with difficulty)  
3. Sometimes mild burn, tan about average  
4. Rarely burn, tan more than average (with ease)  
5. Don’t know  
 
3. What is the natural colour of your hair as a young adult?                                             4. What colour are your eyes? 
1. Black  
2. Brown  
3. Gray, green  
4. Blue  
5. Hazel  
 
5. In the past, in summer, how often did your activities (playing, participating in sports, watching sports, gardening,  walking, 
work activities, etc.) take you outside at the following ages? 
 Not that often Reasonably often Quite often Virtually all the time Don’t know 
0-5 yrs      
6-10 yrs      
11-15 yrs      
16-20 yrs      
21-25 yrs      
26-30 yrs      
In the past 3 years      
 
6a.  In the past, in winter, how often did your activities (playing, participating in sports, watching sports, shovelling snow, 
walking, work activities, etc.) take you outside at the following ages? 
 Not that often Reasonably often Quite often Virtually all the time Don’t know 
0-5 yrs      
6-10 yrs      
11-15 yrs      
16-20 yrs      
21-25 yrs      
26-30 yrs      
In the past 3 years      
 
6b. On weekends and holidays, how much time did you normally spend outside at the following ages: 
 Never Less than 1 hour/day 
1-2 
hours/day 3-4 hours/day 
More than 
4hours/day Don’t know 
0-5 yrs       
6-10 yrs       
11-15 yrs       
16-20 yrs       
21-25 yrs       
26-30 yrs       
In the past 3 years       
 
7. At the following ages, where have your work and occupational activities (including parenting, caregiving, etc.) been carried out: 
 Mainly indoors Mainly outdoors Equal time spent indoors and outdoors 
16-20 yrs    
21-25 yrs    
26-30 yrs    
 
1. Black  
2. Dark Brown   
3. Light Brown  
4. Blonde  
5. Red  
   SECTION 2: SUN EXPOSURE   
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8. How often did you go on vacation to sunny places during winter months at the following ages? 
 Never/seldom 1week/year or less 1-2 weeks/year 4+ weeks/year 
0-5 yrs     
6-10 yrs     
11-15 yrs     
16-20 yrs     
21-25 yrs     
26-30 yrs     
In the past 3 years     
 
 
9. How often did you use sun protection (sunscreen or protective clothing such as hats, long sleeves) at the following ages?  
 Never/Seldom Sometimes Quite often Almost always Don’t know 
0-5 yrs      
6-10 yrs      
11-15 yrs      
16-20 yrs      
21-25 yrs      
26-30 yrs      
In the past 3 years      
 
 
10. How often did you use sunlamps or tanning beds at these ages? 
 Never/Seldom Less than once/year Less than once/month Once or more/month 
16-20 yrs     
21-25 yrs     





We would like to ask you information about your diet when you were a “teenager” (between 13 and 19 years old). If your diet changed 
substantially during this period of time, please try to report the average consumption for the period. 
 
1.  Please indicate in which season(s) you generally consumed the following foods while you were a teenager (age 13-19 years)? 
 (you may choose more than one checkbox per row) 
 
Winter Spring Summer Fall 
Never/ 
seldom 
Cows’ milk (liquid or reconstituted powdered)      
Other type of milk (Specify: ___________________________)      
Yogurt      
Eggs (prepared any style)      
Fresh cheeses (e.g., fresh ricotta, cottage cheese, cream cheese)      
Aged cheeses (e.g., Parmesan, strong cheddar)      
Smoked cheeses (e.g., smoked gouda)      
Other cheeses (e.g., cheddar, marble, feta, havarti, mozzarella, 
Monterey Jack, gouda, pecorino, Gloucester, Cheshire) 
     
Red meat (e.g., beef, lamb, venison, bison) or cold cuts (of all 
types) 
     
Smoked meat & pork      
Hotdogs, frankfurters, weiners      
Fresh fish      
Frozen fish      
Preserved fish (in oil, in salt, dried)      
Smoked fish      
Shellfish:      
   (i) Molluscs (cuttlefish, octopus, squid, mussels, clams, oyster, 
scallops, etc.) 
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2a.  Please indicate how often you generally ate the following foods while you were a teenager (age 13-19 years). 











More than 3 
times/ week 
Cow’s milk (liquid or reconstituted powdered)       
Other type of milk (Specify: __________________)       
Yogurt       
Eggs (prepared any style)       
Fresh cheeses (e.g., fresh ricotta, cottage cheese, cream 
cheese) 
      
Aged cheeses (e.g., Parmesan, strong cheddar)       
Smoked cheeses (e.g., smoked gouda)       
Other cheeses (e.g., cheddar, marble, feta, havarti, 
mozzarella, Monterey Jack, gouda, pecorino, 
Gloucester, Cheshire) 
      
Red meat (e.g., beef, lamb, venison, bison) or cold cuts 
(of all types) 
      
Smoked meat & pork       
Hotdogs, frankfurters, weiners       
Fresh fish       
Frozen fish        
Preserved fish (in oil, in salt, dried)       
Smoked fish       
Shellfish:       
   (i)  Molluscs (cuttlefish, octopus, squid, mussels, clams, 
oyster, scallops, etc.) 
      
   (ii) Crustaceans (prawns, scampi, lobster, shrimp, crab,  
         etc.) 
















More than 3 
times/ week 
Fresh or frozen salmon (not including smoked or canned)       
Canned salmon       
Fresh or frozen tuna (not including canned)       
Canned tuna       
Trout, Carp       
Halibut       
Sardines, anchovies       
Fresh or frozen mackerel       
Cod        
Herring        
Grouper, swordfish        
Flounder, sole, smelt       
Pickerel, snapper, perch       
Other: specify _______________       
 
 
3. What type of water did you usually use when you were a teenager (age 13-19 years)? (you can check more than one box per row) 
 
 
No Consumption For drinking For cooking 
To make coffee/ 
tea/ hot drinks 
Well water, spring water.     
Tap water     
Bottled water     
Don’t know     
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4. How often did you use the following condiments and oils as a teenager (age 13-19 years) including as dressings, or sauces, and for cooking?  
    (Please check only one box per row)  








More than 5 
times/week 
Butter        
Margarine        
Lard        
Mayonnaise        
Vegetable oils:        
  (i) Corn, sesame, walnut, 
sunflower, flaxseed, safflower oil 
       
  (ii) Canola, peanut, olive, coconut, 
avocado, almond oil 
       
  (iii) Other vegetable oils: 
    Specify: __________ 
       
 
5.  Did you take any of the following dietary supplements when you were a teenager (age 13-19 years)?  
 Yes  No Don’t know 
Cod liver oil liquid    
Cod liver oil capsules    
Fish oil capsules    
Multivitamins     
Calcium    
Vitamin B12    
Vitamin C    
Vitamin D    
 
6. Please report what you were fed as a baby.     (You can select more than one box per column and line.) 
 
Breast milk Artificial formula 
Other milk (e.g. 
cow, soy, etc.) 
Don’t know 
From 1-3 mths     
From 4-6 mths     
From 7-9 mths      
From 10 mths & older     





The following questions concern illnesses that you may have had when you were younger.  
 
1. Please indicate at what age you had the following illnesses or surgical interventions. To help you remember, think about which school grade 
you were in when you had the illness/surgery.  Check all that apply. 





  Did     
 have 
0-5 yrs 6-10 yrs 11-15 yrs 16-20 yrs 21-25 yrs 26-30 yrs 
Measles   →       
Mumps   →       
Rubella (German Measles)   →       
Chicken pox   →       
Tonsillectomy (tonsil removal)   →       
Pneumonia (check as many 
times as applies) 
  →       
2a. Have you had infectious mononucleosis (also called “mono” or “the 
kissing disease”)?  
   Yes   No     Don’t know         If no or don’t know, 
    →go to question 2b                                 skip to question #4 
 
2b. If yes, did have a blood test to check the diagnosis?  
Yes No Don’t remember 
             
 
2c. At what age did you have mononucleosis? 
  0-5 yrs     6-10 yrs   11-15 yrs    16-20 yrs    21-25 yrs   26-30 yrs 
      
 
 3a. Do you remember in which month you were diagnosed with mono?    
                   No        Yes      if yes, in which month was it? 
 
           → If you know the month, skip to question #4. 
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3b. If you don’t remember the exact month, can you recall in which season you had mono?    
Spring Summer Fall Winter Don’t Remember 
     
 
4. Have you ever had a urinary tract infection (UTI)? If yes, please give your best estimate of the age(s) when it/they occurred.  
 Ages when UTI occurred. (you can check more than one box in the same row) 
No Don’t know  Yes 0-5 yrs  6-10 yrs 11-15 yrs 16-20 yrs 21-25 yrs 26-30 yrs 
  →       
 
5. Have you ever had a parasitic infection (e.g., Tenia or tapeworm, ossiuri, ascarides, giardia, cryptosporidium, etc.)?   
     If yes, please give your best estimate of your age when it first occurred. 
 Age of first infection 
No Don’t know  Yes 0-5 yrs 6-10 yrs 11-15 yrs 16-20 yrs 21-25 yrs 26-30 yrs 
  →       
 
6. Do you have a history of allergy (such as conjunctivitis or red itchy watery eyes, rhinitis or runny nose, eczema, hives, asthma) to 
any of the following?  
      If yes, please estimate the approximate age at which you experienced the first symptoms (i.e., when did the allergies begin?).  
    Age at first symptoms 
 No Don’t know  Yes 0-5 yrs 6-10 yrs 11-15 yrs 16-20 yrs 21-25 yrs 26-30 yrs 
Pollens   →       
House dust   →       
Animal dander/fur   →       
Any food   →       
Other allergies 
Specify: _____________   →       
 
7. Has a doctor ever told you that you had any of the following disorders? 
 No Don’t know    Yes Age at diagnosis Age at first symptoms 
Systemic lupus erythematosus (Lupus)    → yrs yrs 
Rheumatoid arthritis    → yrs yrs 
Hypothyroidism    → yrs yrs 
Hyperthyroidism    → yrs yrs 
Multiple sclerosis    → yrs yrs 
Optic neuritis    → yrs yrs 
Crohn’s disease    → yrs yrs 
Ulcerative colitis    → yrs yrs 
Type I diabetes mellitus (juvenile diabetes)    → yrs yrs 
Celiac disease    → yrs yrs 
Psoriasis    → yrs yrs 
Leukemia    → yrs yrs 
Hodgkin’s lymphoma    → yrs yrs 
Non Hodgkin’s lymphoma    → yrs yrs 
Melanoma skin cancer    → yrs yrs 
Non-melanoma skin cancer    → yrs yrs 
Kidney disorders    → yrs yrs 
Other medical disorders, 
     specify: ________________    → yrs yrs 
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8. To your knowledge, does anyone in your family have a history of any of the following diseases? 
 No Father Mother Brother/Sister Child Don’t know 
Systemic lupus erythematosus (lupus)       
Rheumatoid arthritis       
Hypothyroidism       
Hyperthyroidism       
Multiple sclerosis       
Optic neuritis       
Crohn’s disease       
Ulcerative colitis       
Type I diabetes mellitus (juvenile diabetes)       
Celiac disease       
Psoriasis       
Leukemia       
Hodgkin’s lymphoma       
Non Hodgkin’s lymphoma       
 
 
1. Have you ever been a regular smoker? (“regular” = smoked one or more cigarettes per day for 6 months or longer) 
Yes No 
  → If your answer is no skip to question #5. 
 
2. If yes, how many cigarettes per day on average did you smoke at the following ages? 
 0 cig./day 1-4 cig./day 5-10 cig./day 11-20 cig./day 21+ cig./day 
11-15 yrs      
16-20 yrs      
21-25 yrs      
26-30 yrs      
 
3. At what age did you start to smoke cigarettes daily?         3a. Do you still smoke?      4. How many years have you smoked in total? 
   (Age)          Yes        No               (Number of years)                     
                                                                                                                       
 
5. Did your mother smoke while she was pregnant with you? 
No Don’t know Yes → How many cigarettes per day did she smoke? 
            Less than 10           10+           
 
6. Did your mother smoke inside the house when you were a child?   
She was a non-smoker No, she didn’t Don’t know Yes→ If yes, how many cigarettes per day did she smoke inside the house? 
                    Less than 10           10+            
 
7. Did your father smoke inside the house when you were a child? 
He was a non-smoker No, he didn’t Don’t know Yes → If yes, how many cigarettes per day did he smoke inside the house? 
                    Less than 10         10+                     
 
 
8. Did you live with anybody else who smoked inside the house before you were age 21? 
No Yes→ Who? How many cigarettes a day did he/she smoke inside the house? 
   Brother      Less than 10           10+  
  Sister          Less than 10           10+  
  Other         Less than 10           10+  
  
9. Did you live with anybody who smoked inside the house when you were between the ages of 21-25 years?  
No Yes→ How many cigarettes per day were smoked inside the house? 
   Less than 10           10+  
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10. Did you live with anybody who smoked inside the house when you were between the ages of 26-30 years?  
No Yes→ How many cigarettes per day were smoked inside the house? 
   Less than 10           10+  
 
 







12. What figure best depicts the shape of your body at the different ages.   
 
                
At 5-years                                        
At 10-years                                        
At 15-years                                        
At 20-years                                        
At 25-years                                        
At 30-years                                        




13. What is your current 
weight? 
   or    







14. How tall are you?     or    
              (Feet    &      Inches)              (Centimetres) 
 
15. What was your level of physical activity per week when you were a teenager (between 13 and 19 years old)? (For example, light physical 
activities refer to activities that require light physical effort such as walking leisurely, stretching, vacuuming or light yard work. Vigorous physical 
activities refer to activities that take heavy physical effort such as jogging, running, stair machine, sports (e.g. tennis, basketball, soccer, etc.)).  
 
 None Less than once/week 1-2 times/week 3 or more times/week 
Light physical activity (your heart 
beats slightly faster than normal) 
 
    
Vigorous physical activity (your 
heart rate increases a lot) 
  
    
 
MEN – please proceed to the last question (#14) on page 9 
9.
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1. How old were you when you started getting your period?    
                 Age 
 
2. Are you pregnant now? 
 
Yes   No   
3. Have you ever been pregnant?     Yes           No   Æ if no skip to question #5. 
 
4. If yes, please provide the following information on the outcome of each pregnancy and the year(s). 
 1st pregnancy 2nd  pregnancy 3rd  pregnancy 4th  pregnancy 5th pregnancy 6th pregnancy 
Born alive       
    Breastfed for at least 1 month       
Lost pregnancy (spontaneous or 
induced abortion, interuterine 

























Year of outcome:       
       
 
5. Have you ever undergone hormonal treatment for infertility? 
                                                                           Yes     No  Æ if no skip to question #7 
 
 
6. If yes, please indicate the year(s) you 
received treatment and the number 
of cycles per year. 
           Year(s):  
 
No of cycles/year: 
 
                                             
 
7. Have you ever used a birth control pill (not the “mini-pill” that contains progesterone only, but the type that is taken for 3 weeks, followed 
by 1 week replacement with “sugar-pills”), hormonal patches, vaginal hormonal rings, or hormonal inter-uterine devices (IUD)? 
                                                                             Yes      No  Æ if no skip to question #10 
 
8. If yes, how old were you when you started using these contraceptives?  
Age 
 
9. For how long did you/have you used these contraceptives? 
Less than 1 year 1-3 years 4-5 years 6-9 years 10+ years 
     
 
10. Have you ever suffered from hirsutism, that is, from an excess of coarse hair in areas of the body where it is not normally found (e.g., face, 
chest, back, abdomen)? 
    Yes      Don’t know     No  Æ if no/don’t know skip to last question #14 
 
11. If yes, have you ever been given hormonal therapies to treat this? Yes      No Æ if no skip to last question #14 
 
12. At what age did you start these therapies?              13. For how long did you take these therapies? 
   





14. Lastly, we would like to know if someone helped you fill out the questionnaire. 
 
No         Yes Æ Who?        Mother Father Other 
     
 
  
Less than  
1 year 1-3 years 4-5 years 6-9 years 10+ years 
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Thank you for your participation! 
  
 



































Please return the questionnaire in the enclosed self-addressed envelope to the following address: 
EnvIMS Study 
Neuroepidemiology Research Unit 
1025 Pine Avenue West, Suite P2.028 
Montreal, QC   H3A 1A1 
 
Appendix 2: EnvIMS-Q in Norwegian 
1
Skjemaet skal leses av en maskin. Det er derfor viktig at du legger vekt på følgende ved utfyllingen:
• Bruk blå eller sort kulepenn.
• I de små avkrysningsboksene setter du et kryss for det svaret som du mener passer best, slik: 
• Hvis du mener at du har satt kryss i feil boks, kan du rette det ved å fylle boksen helt, slik: ■
• Der du ikke kan svare på et spørsmål vennligst bruk “Vet ikke” eller “Husker ikke” avkrysningsboksene.
X
1. Hvilket år er du født?
19
SEKSJON 1: BAKGRUNNSDATA
4. Fyll ut kjønn og fødselsår for hvert søsken (inkludert halvsøsken og adoptivsøsken):                         Jeg er enebarn 
 1 2 3 4 5 6
Fødselsår:
Kjønn (M/K) M   K  M   K  M   K  M   K  M   K  M   K 
SEKSJON 2: SOLVANER
5. Om sommeren: Hvor mye utendørsaktiviteter (lek, idrett, tur, hagearbeid, jobb) hadde du? 
            Lite Middels Ganske mye Ute stort sett hele tiden
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     
I de siste tre årene ................     
1. Sett ett kryss på det tallet under fargen som best passer din naturlige hudfarge ved å sammenligne med huden på innersiden av overarmen. 
1 2 3 4 5 6 7 8 9 10
2. Hvordan reagerer huden din første gang du soler deg 
om sommeren hvis du ikke bruker krem med solfaktor? 
1. Jeg blir alltid solbrent og jeg blir aldri brun ...........  
2. Jeg blir vanligvis solbrent og blir mindre
 brun enn andre  .....................................................  
3. Jeg blir av og til solbrent og blir brun
 omtrent som de fl este andre .................................  
4. Jeg blir sjeldent solbrent og blir lett brun  .............  
3. Hva er din opprinnelige hårfarge?
(sett ett kryss) 
1. Svart ...............  
2. Mørkbrun ........  
3. Brun ................  
4. Blond, gul .......  
5. Rød .................  
4. Hvilken øyefarge har du? 
(sett ett kryss) 
1. Svart ...............  
2. Brun ................  
3. Grå, grønn ......  
4. Blå ..................  
2. Hvilken utdanning er den høyeste du, faren din og moren din har fullført?
(sett ett kryss for hver av dere tre)
 Du selv Far Mor
7-årig folkeskole eller mindre .............................    
Grunnskole 9-10 år ..........................................    
Gymnas/ Videregående skole (11-13 år) ................    
Høgskole/Universitet (mer enn 14 år) ....................    
Vet ikke.........................................................    
3. Hvilken etnisk gruppe tilhører dine foreldre       
 Far Mor  Far Mor
1. Norsk/europeisk/annen vestlig ................    4. Afrikansk ............................  
2. Samisk .......................................................    5. Midtøsten  ..........................  










8. Hvor ofte var du på badeferie i ”syden”? 
Alder                      Aldri/sjelden 1 uke i året eller mindre 2-3 uker i året    4 uker eller mer i året
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     
I de siste tre årene ................     
9. Hvor ofte brukte du krem med solfaktor (forsøk å tenke deg et gjennomsnitt)? 
Alder                      Aldri/sjelden  Av og til Ganske ofte Nesten alltid
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     
I de siste tre årene ................     
10. Hvor ofte har du solt deg i solarium? 
Alder Aldri/sjelden Mindre enn 1 gang pr. år Mindre enn 1 gang pr. måned En gang pr. måned eller oftere
16-20 år ......................     
21-25 år ......................     
26-30 år ......................     
SEKSJON 3: KOSTHOLD
Vi er interessert i å få kjennskap til hvordan kostholdet ditt vanligvis var i tenårene (fra 13 til 19 års alder) før du eventuelt fl yttet hjemmefra.
Først vil vi vite hvor ofte du spiste fi sk og ber deg fylle ut spørsmålene så godt du kan.
1. Tilgangen på fi sk kan variere gjennom året. Vær vennlig å markere i hvilke årstider du vanligvis spiste de ulike fi skeslagene
    (sett gjerne fl ere kryss). 
 Vinter Vår Sommer Høst Aldri/sjelden
Torsk, sei, hyse, lyr .....      
Kveite, fl yndre  ............      
Laks, ørret ..................      
Makrell ........................      
Sild .............................      
2. Med tanke på de periodene av året der du spiste fi sk, hvor ofte pleide du å spise følgende til middag? (sett ett kryss pr. linje) 
  Aldri/sjelden 1 pr.mnd. 2-3 pr.mnd. 1 pr.uke 2 pr.uke 3+ pr.uke
Torsk, sei, hyse, lyr .....       
Kveite, fl yndre  ............       
Laks, ørret ..................       
Makrell ........................       
Sild .............................       
7. Hvor mye tid har du tilbrakt utendørs i forbindelse med arbeidet ditt eller studiene dine? 
Alder  Inne stort sett hele tiden Ute stort sett hele tiden Samme tid inne og ute
16-20 år .............................................................................     
21-25 år .............................................................................     
26-30 år .............................................................................     
6. Om vinteren: Hvor mye utendørsaktiviteter (lek, idrett, tur, hagearbeid, jobb) hadde du? 
            Lite Middels Ganske mye Ute stort sett hele tiden
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     







3. Hvor ofte spiste du fi skelever fra du var 13 til 19 år gammel? 
 Aldri   1-3 pr.år       4-6 pr.år   7-9 pr.år 10+ pr.år Vet ikke
             
7. Hva slags fett brukte du vanligvis på brødet?
    (sett gjerne fl ere kryss)
 Brukte ikke fett på   
 brødet  Plantemargarin Smør Vet ikke
    
8. Dersom du brukte fett på brødet, hvor tykt lag pleide du å smøre 
på? (En kuvertpakke med margarin veier 12 gram) (sett ett kryss)
 Skrapet Tynt lag Godt dekket Tykt lag
 (3 g) (5 g) (8 g) (12 g)  
    
5. Da du var 13 til 19 år gammel, hvor mange brødskiver med følgende pålegg spiste du i gjennomsnitt: (sett ett kryss for hver linje) 
 0 pr.mnd. 1-3 pr.mnd. 1 pr.uke 2-3 pr.uke 4-6 pr.uke 7-9 pr.uke 10+ pr.uke
Makrell i tomat, røkt makrell ....         
Kaviar/”Svolvær postei” ..........         
Sardiner, sild, ansjos ...............         
Laks (gravet/røkt) .....................         
Annet fi skepålegg ....................         
4. Da du var 13 til 19 år gammel, hvor ofte spiste du følgende matvarer: (sett ett kryss for hver linje) 
  Aldri Mindre enn 1 pr.mnd. 1-3 pr.mnd. 1 pr. uke 2-3 pr.uke 4+ pr.uke
Kjøtt, (biff, stek, koteletter) og kjøttprodukter
(kjøttkaker, kjøttpudding, pølser) ................         
Røkt kjøtt ....................................................         
Røkte pølser (wienerpølser)  .......................         
Røkt fi sk .....................................................         
Røkt ost ......................................................         
9. Hvor ofte brukte du kosttilskudd da du var 13 til 19 år gammel? For fl ytende tran og tranpiller, vær vennlig å markere i hvilke 
årstider du brukte dem. Dersom du brukte dem hele året, sett ett kryss for vinter, og ett kryss for resten av året. 
 Aldri/sjelden 1-3 pr. mnd. 1 pr. uke 2-3 pr. uke 4-6 pr. uke 7+ pr. uke  
Tran
   Om vinteren .......................        
   Resten av året  ..................        
Tranpiller
   Om vinteren .......................        
   Resten av året  ..................        
Fiskeoljekapsler ....................        
Multivitaminer eller annet
kosttilskudd slik som
Sanasol, Vitaplex, Biovit, 
Kostpluss og Vitamineral ......       
6. Hvor mange brødskiver spiste du hver dag i gjennomsnitt?
11. Hva slags multivitamin/kosttilskudd brukte du i følgende aldere? (sett gjerne fl ere kryss) 
    7-12 år 13-15 år 16-18 år
 Aldri                   0-6 år          (barneskolen)     (ungdomsskolen)    (videregående)          19-24 år           25-30 år
Multivitaminer ...........................          
Kalsium .....................................          
Vitamin D ..................................          
Vitamin B12 ..............................          
Tran/Tranpiller ...........................          
Fiskeoljekapsler ........................          
10. Hvor mye tran pleide du å ta hver gang?
 Brukte ikke tran ½ ts. 1 ts. ½ ss. 1+ ss.
       
12. Ble du ammet?                                                                  Hvor mange måneder?
 Nei Vet ikke Ja 1-3 mnd. 4-6 mnd. 7-9 mnd. 10+ mnd.





  SEKSJON 4: HELSE
                       Ja      Nei      Husker ikke                         Hvis, ja ble det tatt blodprøve for å stille diagnosen?
2. Har du hatt kyssesyken (mononukleose)?                                                                       Ja                        Nei            Husker ikke
                                                                     
       7-12 år 13-15 år 16-18 år  
Hvilken skoleklasse gikk du i da du hadde sykdommen?  0-6 år (barneskolen) (ungdomsskolen) (videregående) 19-24 år 25-30 år
           
                                                              Hvis ikke, husker du ihverfall hvilken årstid det var?
                          Vår         Sommer        Høst            Vinter     Husker ikke
             3. Husker du hvilken måned du hadde kyssesyken (01-12)?                                                               
4. Har du hatt urinveisinfeksjon (blærekatarr)? I så fall, prøv å huske når. 
                                    Alder (sett gjerne fl ere kryss)
 Nei Vet ikke Ja 0-6 år 7-12 år 13-15 år 16-18 år 19-24 år 25-30 år
           ➞      
5. Har du noen gang hatt infeksjon med innvollsormer eller andre parasitter (amøber, bendelorm, mark i magen)
                                    Alder ved start
 Nei Vet ikke Ja 0-6 år 7-12 år 13-15 år 16-18 år 19-24 år 25-30 år
           ➞      
1. Har du hatt noen av følgende sykdommer eller kirurgisk behandling? Prøv å huske hvilken skoleklasse du gikk i da du hadde sykdommen.
    (sett gjerne fl ere kryss)                                   Alder ved diagnose/sykdom
       7-12 år 13-15 år 16-18 år  
   Nei Vet ikke Ja 0-6 år (barneskolen) (ungdomsskolen) (videregående) 19-24 år 25-30 år
Fjernet mandlene .......................             ➞      
Meslinger ...................................             ➞      
Kusma .......................................             ➞      
Røde hunder ..............................             ➞      
Vannkopper ...............................             ➞      
Lungebetennelse .......................             ➞      
6. Har du hatt allergiske reaksjoner (øyekatarr, eksem, høysnue, astma) mot noen av det som er nevnt under? I så fall, angi omtrent 
hvilken alder du først merket disse symptomene
   Nei Vet ikke Ja 0-6 år 7-12 år 13-15 år 16-18 år 19-24 år 25-30 år
Pollen .........................................             ➞      
Husstøv .....................................             ➞      
Allergi mot kjæledyr og husdyr ..             ➞      
Mat ............................................             ➞      
Annen allergi ..............................             ➞      
7. Har du eller har du hatt noen av følgende sykdommer? 
      Alder ved
   Nei Ja Vet ikke første diagnose
Systemisk lupus erythematosus (Lupus)                         år
Reumatoid artritt (leddgikt)                          år
Hypotyreose (lavt stoffskifte)                          år
Hypertyreose (høyt stoffskifte)                          år
Multippel sklerose                          år
Synsnervebetennelse                          år
Crohns sykdom                          år
Ulcerøs colitt                          år
Annet,                         år
presiser: ––––––––––––––––––––––––––––––––––––––––––––
      Alder ved 
   Nei Ja Vet ikke første diagnose
Diabetes mellitus type 1                          år
Cøliaki                          år
Psoriasis                          år
Leukemi (blodkreft)                          år
Hodgkins lymfom                          år
Annen type lymfom                          år
Føfl ekkkreft                         år
Annen type hudkreft                          år








SEKSJON 5: RØYKEVANER OG LIVSSTIL
1. Har du noen gang røykt daglig?  
Ja      Nei, aldri
     Hvis nei, gå til spørsmål 5
11. Har du jobbet med noen som pleide å røyke på din arbeidsplass?  
 Nei Ja
                
5. Da din mor var gravid med deg, pleide hun å røyke?
 Nei Vet ikke Ja           Hvor mange sigaretter
         røykte hun pr. dag?
           ➞     < 10       10 +  
8. Har noen i familien din hatt noen av følgende sykdommer? 
  Nei Far Mor Søsken Barn                              Vet ikke
Systemisk lupus erythematosus (Lupus) .......................       
Reumatoid artritt (leddgikt) ............................................       
Hypotyreose ..................................................................       
Hypertyreose .................................................................       
Multippel sklerose .........................................................       
Synsnervebetennelse ....................................................       
Crohns sykdom .............................................................       
Ulcerøs colitt .................................................................       
Psoriasis  .......................................................................       
Diabetes mellitus type 1 (insulinkrevende sukkersyke) .       
Cøliaki ............................................................................       
Leukemi .........................................................................       
Hodgkins lymfom ..........................................................       
Annen type lymfom .......................................................       
2. Hvis ja, hvor mange sigaretter røykte du igjennomsnitt pr. dag?
    Antall sigaretter hver dag
  Røykte ikke 1-4 sig. 5-10 sig. 11-20 sig. 21+ sig.
11-15 år  .........      
16-20 år  .........      
21-25 år  .........      
26-30 år  .........      
3. Hvor gammel var du da du
begynte å røyke daglig?
Alder:                      år
4. Hvor mange år har du
røykt tilsammen?
                              år
8. Har du bodd sammen med noen andre som pleide å røyke
inne i huset før du var 21 år?  
 Nei Ja                                               
    ➞ Hvem?         Hvor mange sigaretter røykte
             de inne huset pr. dag?
   Bror    < 10   10 +  
   Søster    < 10   10 +  
   Annen    < 10   10 +  
9. Har du bodd sammen med en partner eller noen andre
som pleide å røyke inne i huset fra du var 21 til 25 år?  
 Nei Ja        Hvor mange sigaretter røykte han/hun
              inne i huset pr. dag?                
                              
    ➞    < 10        10 +  
10. Har du bodd sammen med en partner eller noen andre
som pleide å røyke inne i huset fra du var 26 til 30 år?  
 Nei Ja        Hvor mange sigaretter røykte han/hun
              inne i huset pr. dag?               
    ➞    < 10        10 +  
6. Da du var barn, pleide faren din å røyke inne i huset?  
 Han var en   Nei, han røykte                           Hvor mange sigaretter røykte
 ikke-røyker       ikke inne     Vet ikke    Ja        han inne huset pr. dag?        
                                ➞    < 10            10 +  
7. Da du var barn, pleide moren din å røyke inne i huset?  
 Hun var en   Nei, hun røykte                           Hvor mange sigaretter røykte
 ikke-røyker       ikke inne     Vet ikke    Ja        hun inne huset pr. dag?        
                                ➞    < 10            10 +  
12. Hvilket diagram illustrerer best din fi gur på de forskjellige alderstrinn?
  
                        
  
5- år          
10-år ..........          
15-år ..........          
20-år ..........          
25-år ..........          
30-år ..........          
I dag ..........          
14. Hva er høyden din?                                             cm









SEKSJON 7: HORMONELLE FAKTORER
Takk for at du ville delta i undersøkelsen!
15. Hvordan var din fysiske aktivitet i fritiden da du var 13 til 19 år gammel? Tenk deg et ukentlig gjennom-
snitt for året. Skolevei regnes som fritid. besvar begge spørsmålene.
                                                                         timer per uke
    Ingen Under 1 1-2 3 eller fl ere 
Lett aktivietet (ikke svett eller andpusten)    
Hard fysisk aktivitet (svett og andpusten)    
1. Har du på din arbeidsplass vært betydelig eksponert for: 
      Hvor gammel var du da  Hvor mange år har Hva slags arbeid hadde du da
   Nei Vet ikke Ja eksponeringen startet? du vært eksponert? du ble eksponert?
Motorolje                          år                    år –––––––––––––––––––––––––––
Skjæreolje                          år                    år –––––––––––––––––––––––––––
Formolje                          år                    år –––––––––––––––––––––––––––
Hydraulikkolje                          år                    år –––––––––––––––––––––––––––
Turbinolje                          år                    år –––––––––––––––––––––––––––
Asfalt                          år                    år –––––––––––––––––––––––––––
Boreslam                          år                    år –––––––––––––––––––––––––––
Råolje                          år                    år –––––––––––––––––––––––––––
Narkosegasser                           år                    år –––––––––––––––––––––––––––
Organiske løsemidler*                          år                    år –––––––––––––––––––––––––––
*F.eks. avfettingsmidler, trikloroetylen, tetrakloroetylen, white spirit, tynnere, toluen, styren, xylen el. liknende
1. Hvor gammel var du da du fi kk din første menstruasjon?                     år                                                 2. Er du gravid nå?    Nei      Ja  
3. Har du vært gravid?    Nei      Ja     Om svaret er ja, vennligst oppgi utfallet og årstallet for graviditetene.
 Graviditet 1 Graviditet 2 Graviditet 3 Graviditet 4 Graviditet 5 Graviditet 6
Levende født ..................................      
          Ammet du barnet minst
         i en måned? ............................      
Abort (spontan abort eller
provosert abort ...........................      
Dødfødsel ...................................      
                                  
                                     År
5. Har du brukt P-piller (ikke mini-piller) av typen som kan tas i 3 uker
og deretter tas sukkerpiller i 1 uke, P-plaster eller vaginal P-ring?                                     
Nei      Ja   ➞
Hvor gammel var du første gang du brukte slike prevensjonsmidler?                    år                 
                                                                                                                                                     
                                                                                                                        
 Hvor lenge brukte du slike prevensjonsmidler?
< 1 år       1-3 år        4-5 år        6-9 år         10+ år
                                                      
1. Helt til slutt vil vi gjerne vite om du har fått informasjon  fra andre ved utfylling av dette skjemaet, f.eks. din mor?
 Hvis ja, hvem? Mor 
 Far 
 Andre   






Appendix 3: Lifestyle questionnaire in the OFAMS 
follow-up study  
 
Pasient- ID: ___________________       Initialer: _______________      Dato: _____________ 




Sted:  ____________________________________              
 
Fødselsdato (dd.mm.yy): ________________________ 
 
Kjønn:   ☐ Mann    ☐ Kvinne  
 
I vår studie ønsker vi å vurdere hvordan livsstilsfaktorer kan påvirke forløpet ved MS. 
I dette spørreskjemaet vil du derfor bli bedt om å besvare spørsmål vedrørende 
bakgrunnsdata og livsstil/kosthold. Vi ønsker at du besvarer spørsmålene så 




SEKSJON 1:  BAKGRUNNSDATA   
 
1. Sivil status (sett kryss): ☐Gift     ☐Samboer    ☐Skilt     ☐Enslig 
 
2. Sett kryss for høyest fullførte utdannelse og oppgi alder ved fullføring. Sett et 






Grunnskole: 9-10 år    
Gymnas/videregående skole: 11-13 år    
Høyskole/universitet: 14-16 år    
Høyskole/universitet (masternivå): over 16 år    
 
3. Er du for tiden student, i jobb, arbeidssøkende og/eller ufør ? (sett kryss):   
   
☐ Student     
• Prosentandel: ________%   - Nivå:   ☐Bachelor   ☐Master  ☐PhD 
 
☐ I jobb    
• Stillingsprosent: _________% 
 
• Type jobb:  
☐ Arbeidssøkende 
 
• Tidligere yrke:  
☐ Ufør/ langtidssykmeldt (AAP) fra: måned (0-12): __________ årstall: ________ 
 
• Prosent ufør: _______% 
 
• Årsak ufør/langstidssykmeldt: ☐MS    ☐Annen sykdom     ☐Skade 
Pasient- ID: ___________________       Initialer: _______________      Dato: _____________ 
4. Hvilken etnisk gruppe tilhører du? (sett ett kryss) 
 





Latin-Amerikansk   
Blanding av flere   
 
 
SEKSJON 2: SOLVANER  
 
Vi ønsker å kartlegge dine solvaner i løpet av siste 10 år.  
  
1. Hvor mye utendørsaktiviteter (lek, idrett, tur, hagearbeid) har du i gjennomsnitt 
hatt i sommerhalvåret (fra april-september)? (sett kryss) 
 








For 10 år siden     
For 5 år siden     
Siste året       
 
2. Hvor mange uker i løpet av et år har du vært på ferie til “Syden” for soling og 




1 uke eller 
mindre 2-3 uker 
4 uker eller 
mer Husker ikke 
For 10 år siden       
For 5 år siden      
Siste året        
 




Mindre enn 1 
gang per måned 
1-4 ganger per 
måned 
Mer enn 1 gang 
per uke 
For 10 år siden     
For 5 år siden     
Siste året      
 
4. Har du for det meste jobbet (sett kryss): 
 
 Utendørs  Innendørs Like mye ute som inne  Har ikke jobbet 
For 10 år siden     
For 5 år siden     




Pasient- ID: ___________________       Initialer: _______________      Dato: _____________ 
SEKSJON 3: KOSTHOLD 
 
Vi ønsker å kartlegge dine kostholdsvaner:  
 
1. Hvor ofte har du i gjennomsnitt spist følgende produkter? (sett kryss) 
 
For 10 år siden 
     
 Aldri/ 
sjelden   
1-3 ganger 
per måned   
1 gang  
per uke  
2-3 ganger 
per uke  
4-6 ganger 
per uke  Daglig 
Fet fisk middag *       
Fet fisk pålegg *       
Egg (kokt eller stekt)       
Smør/ margarin i 
matlaging  
      
Helmelk         
Leverpostei       
Gulrot       
Hvitost/Gulost        
Brokkoli       
Paprika        
For 5 år siden  
     
 Aldri/ 
sjelden   
1-3 ganger 
per måned   
1 gang  
per uke  
2-3 ganger 
per uke  
4-6 ganger 
per uke  Daglig 
Fet fisk middag *       
Fet fisk pålegg *       
Egg (kokt eller stekt)       
Smør/ margarin i 
matlaging  
      
Helmelk         
Leverpostei       
Gulrot       
Hvitost/Gulost        
Brokkoli       
Paprika        
I løpet av det siste året   
     
 Aldri/ 
sjelden   
1-3 ganger 
per måned   
1 gang  
per uke  
2-3 ganger 
per uke  
4-6 ganger 
per uke  Daglig 
Fet fisk middag *       
Fet fisk pålegg *       
Egg (kokt eller stekt)       
Smør/ margarin i 
matlaging  
      
Helmelk         
Leverpostei       
Gulrot       
Hvitost/Gulost        
Brokkoli       
Paprika        
* Fet fisk = laks, ørret, kveite, flyndre, makrell, sild, sardiner 
Pasient- ID: ___________________       Initialer: _______________      Dato: _____________ 
2. Hvordan vil du definere ditt kosthold? (sett kryss) 
 
 For 10 år 
siden 
For 5 år 
siden   I dag  
1. Spiser både kjøtt, fisk og meieriprodukter    
2. Spiser fisk og meieriprodukter, men ikke kjøtt     
3. Vegetarianer som spiser meieriprodukter    
4. Veganer som ikke spiser animalske produkter    
 
 
3. Har du brukt kosttilskudd som inneholder vitaminer*? (sett kryss og oppgi evt. 





ikke  Navn på produkt(er) 
For 10 år siden     
For 5 år siden     
Siste året     
* Vitamin D-tabletter, trankapsler, tran, vitaminbjørner, multivitaminer, andre vitamin-tilskudd  
 
 
4. Hvilke(t) kosttilskudd i tabellen har du brukt mest på de ulike tidspunkt? (sett flere 
kryss om du har brukt flere typer like mye)  
 
 For 10 år siden For 5 år siden Siste året  
Vitamin D tabletter    
Trankapsler    
Tran      
Vitaminbjørner      
Andre multivitamin-
produkter 
   
Brukte ikke slike tilskudd    
 
 
5. Hvor ofte har du brukt kosttilskudd som oppgitt i punkt 4 i vinterhalvåret 
(oktober-mars)? (sett kryss) 
 
 For 10 år siden For 5 år siden Siste året  
Aldri/ sjelden    
1-3 dager per 
måned 
   
1-3 dager per uke    
4-6 dager per uke    
Daglig      






Pasient- ID: ___________________       Initialer: _______________      Dato: _____________ 
6. Hvor ofte har du brukt kosttilskudd som oppgitt i punkt 4 i sommerhalvåret     
(mai til august)? (sett kryss)  
 
 For 10 år siden For 5 år siden Siste året  
Aldri/ sjelden    
1-3 dager per 
måned 
   
1-3 dager per uke    
4-6 dager per uke    
Daglig      
Husker ikke         
 
 
SEKSJON 4: RØYKING OG SNUSBRUK  
 
Vi ønsker å kartlegge dine røyke- og snusvaner:  
 
1. Røyker du nå?  ☐Ja      ☐Nei    
 
2. Har du røykt i løpet av siste 10 år?  ☐Ja     ☐Nei   (ved Nei- gå til punkt 6).  
 
3. Hvis “ja” i punkt 2- hvor mange av de siste 10 årene har du røykt? _____ av 10 år.  
 
4. Hvor ofte har du røykt/røyker du i gjennomsnitt? (sett kryss)  
 





per uke Daglig 
Røykte 
ikke 
For 10 år siden      
For 5 år siden      
Siste året       
 




1- 4 sigaretter 5-10 sigaretter 11-20 sigaretter 
Over 20 
sigaretter 
For 10 år siden     
For 5 år siden     
Siste året      
 
6. Snuser du nå?  ☐Ja       ☐Nei    
 
7. Har du snust i løpet av siste 10 år? ☐Ja       ☐Nei   (ved Nei- gå til seksjon 5) 
 





Pasient- ID: ___________________       Initialer: _______________      Dato: _____________ 
9. Hvis du har snust- hvor ofte har du snust i gjennomsnitt? (sett kryss) 
 
 1-3 dager  
per måned  
1-2 dager 
per uke  




For 10 år siden      
For 5 år siden      
Siste året       
 
 
SEKSJON 5: FYSISK AKTIVITET 
 
1. Hvor ofte har du i gjennomsnitt trent/ vært så fysisk aktiv at du har fått økt puls og 
blitt svett og andpusten? (sett kryss) 
 
 
Kun sporadisk   
1-2 timer per 
uke 
3-5 timer per 
uke 
6 timer eller 
mer per uke  
For 10 år siden     
For 5 år siden     
Siste året     
Siste måned          
 
2. Hva slags fysisk aktivitet (som har medført økt puls + svett og andpusten) har du 






For 10 år siden   
For 5 år siden   
Siste året   
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